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Abstract of Dissertation 
Multidrug resistance-associated protein 1 (MRP1) is a member of the 
adenosine 5’-triphosphate (ATP)-binding cassette (ABC) transporters.  MRP1 
actively effluxes a variety of endogenous and exogenous substrates from cells, 
ultimately, working to remove these compounds from the body.  MRP1 was 
initially discovered based on its ability to confer resistance against a variety of 
chemotherapeutics when overexpressed in cancer cells lines. MRP1 function is 
important for a number of physiological processes, including regulating cellular 
and extracellular levels of the anti-inflammatory leukotriene C4 (LTC4) and the 
antioxidant glutathione (GSH). Our studies have focused on the role of MRP1 in 
regulating hematopoietic stem cell (HSC) self-renewal and differentiation and the 
role of CK2 as a regulator of MRP1 function. Reactive Oxygen Species (ROS) 
cellular levels are tightly regulated and fluctuations in ROS levels affect many 
cellular processes, including the self-renewal and differentiation of hematopoietic 
stem cells and kinase signaling pathways. MRP1 regulates ROS through the 
transport of reduced and oxidized GSH.  MRP1 is highly expressed in HSCs, 
therefore we hypothesized that MRP1 regulates ROS levels in HSCs via efflux of 
GSH. We have shown that MRP1 regulates HSC self-renewal by modulating 
cellular ROS via the efflux of GSH.  The decrease in ROS results in 
downregulation of p38 activity and altered expression of a number of redox 
response genes.   
CK2 is a master regulator of the cell and controls cell growth, proliferation, 
death and survival. Yeast studies from our lab using Ycf1p (a homologue of 
MRP1) and Cka1p (a homologue of CK2) have found that Cka1p regulates Ycf1p 
function. This result suggests that CK2 regulates MRP1 function via 
phosphorylation. We have found that CK2 does regulate MRP1 function via 
phosphorylation of the N-terminal extension at Thr249.  Using A549, H460, and 
HeLa cancer cell lines, we found that inhibition of CK2 with 
tetrabromobenzimidazole (TBBz) reduces MRP1 function and increases cellular 
toxicity to known MRP1 substrates.  
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Chapter 1 
Introduction 
ATP BINDING CASSETTE TRANSPORTERS: 
Adenosine 5’-triphosphate (ATP)-binding cassette (ABC) transporters are 
integral membrane bound proteins that use ATP as an energy source to move 
endogenous and exogenous compounds across the membranes from cells in 
which they reside (1). There are multiple subfamilies of ABC transporters, ABCA-
ABCG.  Our work has focused on the ABCC subfamily, which includes multidrug 
resistance-associated protein 1 (MRP1).  The ABCC subfamily is comprised of 
13 members, 10 MRPs (MRP1-6/ABCC1-6 and MRP7-10/ABCC10-13), the 
cystic fibrosis transductance regulator (CFTR/ABBC7), and SUR1 (ABCC8) and 
SUR2 (ABCC9).  The ABCC subfamily differs from all other ABC transporters in 
that they have an extended N-terminal region (Figure 1.1)(2). The extended N-
terminus contains either an additional membrane-spanning domain (MSD0) and 
is referred to as long-MRPs, (MRP1-3, 6 and 7) or contains an extended 
cytoplasmic N-terminal domain and is referred to as short MRPs (MRP4, 5, 8 and 
9) (Figure 1.1) (2).  The work described in this thesis focuses on MRP1.  In
addition, we examine and discuss the possible overlap between MRP1 and other 
ABC transporters, such as MRP4. 
MRP4, like MRP1, is ubiquitously expressed in the human body.  In the 
blood, MRP4is expressed in erythrocytes, leukocytes, and blood platelets (3-7).  
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MRP1 and MRP4 have overlapping substrate specificities.  For example, MRP1 
is thought to be the main player in glutathione (GSH) homeostasis, however, a 
study done by Bai et al. has shown that MRP4 is also capable of transporting 
GSH alone, as well as, GSH conjugates (8).   
 
ABC Transporters and Disease:   
 
Mutations in numerous transporters have been shown to result in diseases 
such as Cystic Fibrosis, Stargardts disease, and Dubin Johnson’s syndrome, 
while overexpression of many of the ABC transporters results in cancer multidrug 
resistance (9). Some transporters upregulated in cancer include, but aren’t 
limited to, ABCB1, ABCC1/MRP1, ABCC2, ABCC3, ABCC4, ABCC5, and 
ABCG2 (1).  The ability of these ABC transporters to efflux a wide range of 
chemotherapeutics has resulted in extensive investigation of their roles in 
multidrug resistance and their potential as chemotherapeutic targets (10).  It is 
important to note that for many of the ABC transporters the correlation between 
transporter expression and multidrug resistance in cancer is often small and 
limited to specific cancer subtypes.  Despite their promise as chemotherapeutic 
targets for some specific cancers, development of therapeutic drugs that 
effectively inhibit transporter function has achieved less than the desired results.  
Transporter research continues to expand beyond its traditional focus on 
multidrug resistance as new cellular roles are being discovered (11, 12).  
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 Regulation of ABC transporters 
 
A critically important area of investigation is ABC transporter post-
translational regulation, most commonly through phosphorylation (13, 14). 
Phosphorylation plays an important role in many cellular processes, including the 
regulation of transcription, ubiquitination, degradation, localization, and protein 
function (15).  Due to the large size of ABC transporters and the resulting high 
number of potential phosphorylation sites, studying ABC transporter 
phosphorylation has been extremely difficult. In recent years, with the 
improvement in protein purification techniques and mass spectrometry, several 
phosphorylation sites in ABC transporters have been identified; these are 
reviewed in Stolarczyk et al. and are summarized in Table 1.1(14).  
 
MRP1 
 
The ABC transporter MRP1 was first discovered from the drug resistant 
cell line H69AR, in which the resistance was not due to the transporter P-gp (16). 
MRP1 is ubiquitously expressed in the mouse and human body especially in the 
lung, heart, kidney, testes, blood and skeletal muscles (3-7). In the blood MRP1 
can be found in erythrocytes, leukocytes, and blood platelets (3-7). MRP1 is a 
long-MRP roughly 190 kDa in size and overexpression of MRP1 can decrease 
cellular toxicity of a broad range of compounds via cellular efflux.  Substrates of 
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MRP1 include both xenobiotics and endogenous toxins made within the cell.  
Many of the substrates of MRP1 are chemical conjugates of a toxin with sulfate, 
GSH or glucuronate, or are co-substrates with GSH (17).  
 
MRP1 (GS-X transporter)  
 
One very important function of MRP1 is its role in GSH homeostasis. 
Although initially MRP1 was shown to transport GSH-chemical conjugates, it has 
since become evident that MRP1 can also transport GSH as a co-substrate or 
transport GSH alone (17).  MRP1 is a low affinity and high capacity transporter of 
GSH (18-20). Intercellular concentrations of glutathione is around 5 mM (19-21). 
Interestingly, the Km for GSH (reduced) is estimated to be around 5-10 mM and 
the Km for GSSG (oxidized) is closer to 50-100 µM, ie ranges almost identical to 
cellular concentrations (18-20).  
Intracellular levels of GSH are increased in MRP1 null mice, particularly  in 
tissues that typically have high MRP1 expression, including the breast, lung, 
heart, kidney, muscle, colon, testes, bone marrow cells, blood mononuclear 
leukocytes, and blood erythrocytes (21).  The increase of basal GSH levels is 
thought to be due to decreased GSH export in Mrp1 null mice (22).  Conversely, 
overexpression of Mrp1 decreases cellular levels of GSH due to increased 
MRP1-mediated efflux of GSH (40).   
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Glutathione: 
 
The cell uses protective mechanisms to deal with reactive oxygen species 
(ROS).  These mechanisms include both non-enzymatic systems, such as GSH 
and enzymatic protective mechanisms, such as SOD1-3, catalase, and 
glutathione peroxidase (6) (Figure 1.2). For the purpose of our work, we have 
focused on the cellular antioxidant, GSH.  
GSH is a tripeptide that consists of the amino acids L-cysteine, L-glutamic 
acid, and glycine (23). In the first and rate-limiting step of glutathione synthesis, 
L-cysteine and L-glutamate are utilized by the enzyme glutamyl cysteine ligase 
(GCL) to make gamma-glutamylcysteine (23). GCL is composed of two subunits: 
catalytic (GCLC) and modulary (GCLM) (23). After gamma-glutamylcysteine is 
made, the enzyme glutathione synthetase (GSS) adds glycine in the final step of 
GSH synthesis (23).   
GSH exists in two forms, reduced glutathione (GSH) and oxidized 
glutathione (GSSG) (24). When in the reduced form cysteine is able to donate a 
H-radical to ROS, such as OH., H2O2, and O2. thereby stabilizing its reactivity 
(25). In a healthy environment the majority of GSH will be in the reduced form 
(6). A shift in the ratio of GSH and GSSG is a sign of oxidative stress (24, 25).  
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 Reactive Oxygen Species 
 
Reactive Oxygen Species, ROS, are subdivided into two classes: the free 
radical ROS and the non-radical ROS. The free radicals have an unpaired 
electron in their outer orbital and examples include O2- and HO. (26, 27). The 
non-free radical ROS do not have unpaired electrons in their outer orbitals, but 
can become reactive. Examples of non-free radical ROS include hydrogen 
peroxide (H2O2), ozone (O3), and hydroxide (OH) (26, 28).  
ROS are known to play important roles in regulating cellular functions, 
including regulation of cellular growth arrest, increased cellular proliferation, 
senescence, apoptosis and necrosis.  Cellular damage caused by ROS includes 
lipid peroxidation, DNA adduct formation, protein oxidation, and enzyme 
inactivation, which can lead to apoptosis (29). Excess ROS can cause 
irreversible peroxidation of lipids, amino acids, nucleic acids, and carbohydrates 
(30). Although excess ROS is associated with having negative consequences in 
the cell, a certain level of ROS is needed to maintain the normal physiological 
processes of the cell, such as defense against infectious agents and the 
induction of signaling pathways (31). The bone marrow (BM) microenvironment is 
hypoxic with levels of O2 in the 0.1-4% range (32, 33). In less hypoxic tissues the 
physiological levels of O2 are below 6% (34). In the quiescent state of 
hematopoietic stem cells (HSCs) the level of O2 is typically the lowest at 0.1% 
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(35). When ROS exceeds these physiological levels it can lead to diseases, such 
as cancer, cardiovascular disease, as well as aging.  
 
 
Hematopoiesis/Hematopoietic Stem Cells: 
 
Hematopoietic Stem Cells (HSCs) were the first tissue specific stem cells 
to be identified and remain the most studied of all stem cell types.  Till et al. were 
the first to establish the components necessary for blood regeneration (36).   
Their definition of an HSC from 1961 still holds today:  a cell that can self-renew 
and differentiate to all the blood cell types (36).  Another important feature of 
stem cells is their ability to repopulate the bone marrow of lethally irradiated 
animals and people (37).   
HSCs are found in the bone marrow (BM), and despite their ability to 
maintain the balance of blood cells, they compromise only 1:10,000 cells in the 
BM (38-40). The bone marrow niche, where the HSCs reside, was defined by 
Schofield in 1978 as “an entity in which the stem cell’s maturation is prevented 
and the properties of ‘stemness’ are preserved” (41). This preservation is the 
result of low oxygen levels that limit the production of ROS.  The main sources 
for ROS in HSCs are NADPH oxidases (NOX) and mitochondria (42, 43). 
Specifically NOX2 is found to be highly expressed in murine bone marrow, and is 
thought to be the NOX most important in ROS regulation and subsequent HSC 
differentiation (42, 43). 
 7 
HSCs can be separated into different categories based on their 
developmental potential and lineage relationships (44).  The more primitive a 
HSC, the more self-renewal capacity it will have. HSCs start as long-term HSCs 
(LT-HSCs) and become more differentiated as they progress to becoming short-
term HSCs (ST-HSCs), multipotent progenitors (MPP) and finally fully committed 
blood cells (45). See Figure 1.3 for a diagram depicting hematopoiesis and the 
three subpopulations of HSC’s.  
 
HSC Identification 
  
 Identifying HSCs can be difficult due to their low numbers.  This is further 
impacted by the inability of HSCs to be identified via traditional pathological 
microscopy.  This is due to the small size of HSCs and the similar appearance of 
HSCs to other blood and BM cells (45). In 1988 Irving Weismann’s group at 
Stanford was the first to identify a set of cell surface markers that could be used 
to identify murine HSCs via flow cytometry. Their markers were CD34 low/-, Sca-
1+, Thy+/low, CD38+, C-Kit+, and Lin- (45). See Table 1.2 for commonly used 
protein surface markers in HSC research, and their definition. 
 Prior to protein surface markers being identified, researchers would carry-
out transplantations of cells they thought contained HSCs into irradiated mice.   A 
functional hematopoietic system would be restored if HSCs were present in the 
transplanted cells (36). The experimental design for transplantations is depicted 
in Figure 1.4. Discrepancy in the best markers for use during FACS analysis for 
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HSCs necessitates the testing of a stem cell’s ability to self-renew via 
transplantation studies.  Therefore, transplantation studies have remained the 
“gold” standard in HSC murine studies till this day (46). 
 
ROS in HSCs 
 
ROS have been shown to play a role in regulating HSC self-renewal and 
differentiation.  Previous work has established that hydrogen peroxide is a major 
player in ROS-mediated signaling and ROS-induced cellular affects in HSCs 
(47). Low levels of hydrogen peroxide are needed to maintain the physiological 
processes of the HSCs, but excess of hydrogen peroxide can lead to increased 
cellular proliferation, senescence, and apoptosis (47). See Figure 1.5 for a 
diagram of how oxidative stress impacts the differentiation of HSCs. The low 
numbers of HSCs make it difficult for ROS to be directly measured in those cells. 
Previous studies using 2’-7’-dichlorodihydrofluorescein diacetate (DCF-DA), used 
to measure the redox status of the cell, have found that DCF-DA high HSC 
populations tend to behave like aged HSCs.  Importantly, the DCF-DA low 
populations have high self-renewing capacity, are more quiescent in character, 
and are often found in the HSC niche (48). 
 ROS serve as a promising treatment target for cancer stem cells. ROS 
levels can be manipulated using xenobiotics to target and subsequently destroy 
cancer cells and cancer stem cells. For example, drugs that increase ROS levels, 
such as Niclosamide, can selectively kill leukemic stem cells (LSCs) while having 
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minimal cytotoxicity against normal HSCs (49).The ability of Niclosamide to 
target leukemic stem cells is due to the ability of Niclosamide to inhibit the NF-κB 
pathway, and NF-κB has been found to be activated in the primitive blast cells in 
AML patients (49). Additionally, Niclosamide has been found to increase ROS in 
AML cells resulting in apoptosis (49).  Studies have shown that ROS-mediated 
cell senescence may be acting through the p38 mitogen-activated protein kinase 
(MAPK), which is known to activate NF-κB (50). 
 
 
p38 MAPK Pathway 
 
 The p38 MAPK pathway has been found to play a role in cell cycle arrest, 
apoptosis, differentiation, and senescence (51).  p38 MAPK was identified by 
Han et al. in 1994 during a pharmacological screen used to identify compounds 
that modulate tumor necrosis factor (TNFα) production (52).  Phosphorylation, by 
either mitogen-activated protein kinase kinase (MKK)3 or MKK6 at Thr180 or 
Tyr182, is required to activate p38 MAPK (53). Once activated, p38 MAPK 
phosphorylates and activates downstream targets, such as mitogen-activated 
protein kinase activated protein (MAPKAP) Kinase 2 (54). Additionally, p38 
phosphorylates and activates transcription factors such as activating transcription 
factor 2 (ATF), p53, and myocyte enhancer factor 2 (MEF2) (Figure 1.6)(54).   
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N-Acetyl Cysteine (NAC) 
 
Cysteine is the rate-limiting amino acid in the synthesis of GSH and is required 
by gamma glutamyl ligase, the enzyme that catalyzes the synthesis of cysteine-
gamma glutamyl. GSH synthesis is stimulated with a synthetic thiol, N-Acetyl 
Cysteine (NAC). NAC easily passes through cell membranes and becomes 
deacetylated in tissues/cells to form cysteine (55).  Besides stimulating GSH 
synthesis by providing cysteine, NAC is a ROS scavenger, forming NAC-disulfide 
products (56).  Additionally, NAC has the ability to restore HSC self-renewal, 
which is thought to be through the p38 MAPK pathway (48). 
 
 
CK2 
 
 CK2 is a serine/threonine protein kinase. It forms a tetrameric complex, 
but its individual subunits can be active on their own (57).  The complex is made 
of two catalytic α and two regulatory β units (57).  CK2 has over 300 substrates 
and plays a role in a variety of cellular processes including cell growth, 
proliferation, death, and survival (58). It has been established that CK2 can 
phosphorylate ABC transporters, such as ABCA1 and ABCB1/Pgp (59, 60). The 
diverse roles of CK2 have led to CK2 being nicknamed a “master regulator of the 
cell.” Increased protein expression of CK2 is found in all cancers that have been 
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studied (58, 61). CK2 has gained interest as a “druggable” target for leukemia 
treatment due a small number of studies that have shown that CK2 inhibitors 
target leukemic stem cells selectively (62, 63).  
Our laboratory has previously used MRP1’s yeast homolog, Ycf1p, to 
demonstrate that Cka1p, the yeast homolog to CK2α, could regulate transporter 
function during salt stress. This regulation was due to Cka1p phosphorylating 
Ser251 at the L0 region (Figure 1.7)(64). Additionally, our laboratory has shown 
that Cka1p-mediated phosphorylation of Ycf1p results in decreased ROS due to 
increased GSH (65). The increase of GSH was due to a loss of Ycf1p-mediated 
GSH transport (65).  
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Research Objectives 
 
Drug transporters such as MRP1 play an important role in both the 
detoxification of endogenous and exogenous toxins, efflux of cellular signaling 
molecules, and in drug resistance in cancer(1).  In Chapter 2 we will discuss the 
role of MRP1 in the regulation of hematopoietic stem cell differentiation and self-
renewal. Chapter 3 will discuss the role of CK2-mediated post-translational 
phosphorylation of MRP1 as a mechanism of regulating transporter function. 
 
The aims of chapter 2 were as follows: 
1. Characterize HSC function in MRP1+/+ and MRP1-/- C57BL6 mice. 
2. Determine the role of MRP1 in regulating HSC self-renewal and 
differentiation    
3. Determine the mechanism by which MRP1 regulates HSC self-renewal 
and differentiation. 
  
 Here, using flow cytometry, we found that deletion of MRP1 increases the 
frequency of LT-HSCs, ST-HSCs, and multipotent progenitors (MPPs)in bone 
marrow (BM). Further, deletion of MRP1 increases the ability of HSCs to 
repopulate the BM of lethally irradiated mice due to an increase in HSC self-
renewal, as determined by serial dilution competitive repopulation assays. We 
provide strong evidence that the mechanisms by which self-renewal increases in 
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MRP1-/- mouse HSCs include: 1) decreased cellular ROS, 2) decreased p38 
signaling, and 3) altered redox response protein expression, all due to increased 
GSH levels. We provide additional evidence to support our model in experiments 
aimed at recapitulating the MRP1-/- mouse HSC phenotype via administration of 
the antioxidant NAC. NAC treatment decreased cellular ROS levels and 
increased the number of LT-HSCs and ST-HSCs, similar to what we have seen 
in the MRP1-/- mouse HSCs. Overall, the data from this study strongly suggest a 
role for MRP1 in regulating HSC self-renewal via efflux of GSH and subsequent 
decreased levels of ROS. 
 
The aims of Chapter 3 were as follows: 
1. Screen several different types of cancer derived cell lines for expression of 
MRP1 and CK2.  
2. Determine if MRP1 function is inhibited by treatment of cancer cell lines 
with CK2 inhibitors. 
3. Determine if treatment of cell lines with CK2 inhibitors decreases MRP1-
mediated drug resistance in standard cytotoxicity assays  
 
        Here, we found that A549, HeLa, and H460 cell lines expressed MRP1 and 
CK2.   Doxorubicin (Dox) accumulation assays and cytotoxicity assays were 
used to measure MRP1 function.  To effectively measure MRP1 function in the 
context of a multidrug transporter setting of each cell line, we used an MRP1 
inhibitor, MK571, to block MRP1-dependent Dox transport and provide a baseline 
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for comparison for Dox accumulation when MRP1 is maximally inhibited. These 
experiments were conducted in the presence and absence of a CK2 inhibitor.  
We found that inhibition of CK2 reduced MRP1-dependent Dox efflux and MRP1-
dependent protection against Dox cytotoxicity.  
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A. 
 
 
 
 
 
 
 
Figure 1.1: Structure of ABC transporters. A. Half-transporters, such as 
ABCG2, that require dimerization for full function. B) Full length transporters, 
such as Pg-p, MRP4, MRP5, also known as short transporters C) Extended, full 
length transporters, also known as long transporters, that contain an extra 
membrane spanning domain at the N-terminus (depicted as N in the diagrams), 
such as MRP1-3, MRP6.  
 
B 
C 
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Table 1.1.  Phosphorylation sites of the ABC Transporters identified by MS 
analysis of tryptic derived peptides (14) 
TRANSPORTER AMINO ACID SITE 
ABCA1 
SERINE 1042 
THREONINE 1242 
THREONINE 1243 
SERINE 1255 
SERINE 2054 
ABCA2 
SERINE 1327 
SERINE 1331 
THREONINE 2412 
ABCA3 TYROSINE 1265 TYROSINE 1267 
ABCA10 TYROSINE 307 SERINE 568 
ABCB1 
SERINE 661 
SERINE 667 
SERINE 671 
SERINE 686 
ABCB9 SERINE 530 
ABCC1 SERINE 915 SERINE 917 
ABCC2 SERINE 283 SERINE 878 
ABCC4 THREONINE 646 
ABCC5 
SERINE 505 
SERINE 509 
THREONINE 513 
ABCC6 
SERINE 681 
SERINE 902 
SERINE 1310 
ABCC7 
SERINE 422 
SERINE 489 
TYROSINE 515 
SERINE 519 
SERINE 557 
SERINE 641 
SERINE 660 
SERINE 670 
SERINE 686 
THREONINE 690 
SERINE 700 
SERINE 712 
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SERINE 728 
SERINE 737 
SERINE 742 
SERINE 753 
SERINE 756 
THREONINE 757 
THREONINE 760 
SERINE 768 
THREONINE 787 
THREONINE 788 
SERINE 790 
SERINE 795 
SERINE 813 
THREONINE 1176 
ABCC10 THREONINE 463 SERINE 467 
ABCD1 SERINE 733 
ABCD3 TYROSINE 145 
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Table 1.1 Continued
  
 
 
Figure 1.2Model of Oxidative stress response proteins present in cells. 
Glutamate-cysteine ligase catalytic (GCLC), glutamate-cysteine ligase modulary 
(GCLM), glutathione synthetase (GSS) glutathione reductase (GR), glutathione 
peroxidase (GPx), catalase (CAT), superoxide dismutase (SOD) and MRP1 
regulate reactive oxygen species in cells. Furthermore the complex GCLM/GCLC 
is important for the synthesis of GSH, GR is important for recycling glutathione, 
and MRP1 is important for GSH efflux.   
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 Figure 1.3: Hematopoiesis. Hematopoietic Stem Cells are comprised of three 
subpopulations: LT-HSCs, ST-HSCs, and MPP’s.  LT-HSCs are the most self-
renewing and these self-renewing properties decrease as they progress through 
the HSC subpopulations into the common myeloid progenitor, common lymphoid 
progenitor and finally into the fully differentiated blood cell types. Common 
surface markers used to identify blood cells are listed on the following page in 
Table 1.2. Abbreviations used in the above diagram include long-term 
hematopoietic stem cells (LT-HSCs), short-term hematopoietic stem cells (ST-
HSCs), multipotent progenitors (MPPs), common myeloid progenitor (CMP), 
common lymphoid progenitor (CLP), megakaryocyte erythroid progenitor (MEP), 
granulocyte macrophage progenitor, Natural Killer (NK), DC (Dendritic Cell).  
 
 
  
 
 
 
  
 
  
  
      
       
 
  
  
    
 
  
LT-HSC 
ST-HSC 
MPP 
CMP 
MEP 
GMP 
CLP 
Pro-NK Pro-T 
Pro-DC 
Erythrocytes Platelets Macrophages Granulocytes Dendritic Cells T Cells NK Cells B Cells 
HSCs/ 
LSK (Lin-Sca-1+Ckit+) 
Pro-B 
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Table 1.2 Protein Surface Markers for HSCs in mice 
Protein 
Marker 
Subpopulation Expression Identifies 
Lin All: Lin- Lineage Cells/Differentiated 
SCA-1 All: SCA-1+ Stem Cell Antigen. Maintains 
the stem cell population.  
C-Kit All: C-Kit+ Cytokine receptor that binds 
stem cell factor which signals 
growth. 
Proliferation/Differentiation 
CD34 LT-HSCs- CD34- 
ST-HSC/MPP CD34+ 
Mediates attachment to bone 
marrow matrix 
CD135 LT/ST-HSC CD135- 
MPP CD135+ 
Development of B and T 
Cells 
Survival/proliferation/different
iation 
CD150 LT/ST-HSC CD150- 
MPP CD150+ 
Differentiation 
Thy1.1 LT/ST-HSC Thy1.1+ 
MPP Thy1.1- 
Thymocytes, T Lymphocytes 
CD11b LT-HSC-none 
ST-HSC/MPP + 
Monocytes 
CD38 LT-HSC CD38- 
ST-HSC CD38+ 
B lymphocytes, natural killer 
cells 
Ter119 Late MPPs Erythroid Cells 
Gr-1 Late MPPs Granulocytes 
CD45 Late MPPs B-Cells 
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 B.  
 
 
 
 
 
 
 
 
 
Figure1.4 
 
 
 
A. 
Recipient CD45.1  
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 Figure 1.4 Schematic of HSC transplantations: A. Bone marrow is extracted 
from two different strains of mice with differing alleles CD45.1 or CD45.2. The 
wild-type (WT) and knock-out (KO) mouse of interest are CD45.2 positive. The 
recipient mice and helper cells are CD45.1 positive. This will allow us to identify 
the cells of interest from our WT and KO mice after transplantation. To conduct 
the study the bone marrow is mixed together and transplanted into a lethally 
irradiated CD45.1 mouse. The transplanted HSCs are allowed to expand and 
repopulate the bone marrow, as well as blood, for 16 weeks. Flow cytometry can 
be used to analyze the cells derived from the CD45.2 mouse for limiting-dilution 
competitive repopulation studies. These assays allow us to determine the 
frequency of HSCs. B. For serial transplantation studies the principle of the 
transplants are the same, except all mice get the same number of cellsand the 
study extends beyond the first recipient mouse. After analysis at 16 weeks we 
also harvest the bone marrow from the first recipient mouse and transplant it into 
a second irradiated mouse. The bone marrow is allowed to expand and 
repopulate the BM niche and the BM is harvest after 16 weeks. This assay allows 
us to determine the ability of the HSCs to self-renew and repopulate the bone 
marrow niche.  
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Figure 1.5: Model for oxidative stress related changes in HSCs. Increased 
oxidative stress has been shown to play a role in regulating HSC differentiation. 
An increase in oxidative stress coincides with the differentiation of HSCs from 
LT-HSCs to ST-HSCs and finally to MPPs, which ultimately impacts 
hematopoietic self-renewal capacity.  
 
 
 
 
 
 
 
 
LT-HSC ST-HSC MPP 
Self Renewing More Differentiated Self Renewing More Differentiated 
Oxidative Stress 
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Figure 1.6: p38 MAPK pathway. Mitogen-activated protein kinase kinase 
(MKK)3, MKK4 and MKK6 are activated by G-coupled receptors, cytokine 
receptors, reactive oxygen species (ROS), and ultra-violet (UV). Once activated 
they can phosphorylate p38. Once p38 is phosphorylated it becomes active and 
can phosphorylate a number of downstream targets. Shown are some of the 
downstream targets for phosphorylated-p38 (phos-p38) such as p53, activating 
transcription factor 2 (ATF2), myocyte enhancer factor 2 (MEF2), mitogen-
activated protein kinase-activated protein kinase 2 (MAPKAPK2), mitogen and 
stress activated protein kinase 1 and 2 (MSK1/2).  
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Figure 1.7: Ycf1p is regulated by Cka1p-mediated phosphorylation of 
Ser251. Ycf1p consists of 3 transmembrane spanning domains (TMDs) and 2 
nucleotide binding domains (NBDs). Our laboratory has shown that Ycf1p is 
phosphorylated at Ser251 within the L0 domain  by Cka1p (66). 
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Chapter 2 
MRP1 Regulation of Hematopoietic Stem Cell Self-Renewal 
ROS and cellular oxidative stress play an important role in regulating HSC 
self-renewal and differentiation (67-70).  Exposure of HSCs to high levels of ROS 
is toxic and can lead to HSC senescence, apoptosis, and ultimately diseases, 
such as bone marrow failure and leukemia (71-73). Cellular ROS levels are 
regulated by a complex antioxidant system that includes glutathione (GSH), 
catalase (CAT), and superoxide dismutase (SOD).  Low levels of ROS are 
important for maintaining normal HSC differentiation and proliferation (73-76) and 
therefore, HSCs maintain a very tight regulation of cellular ROS and cellular 
antioxidant systems (72). GSH is a key component of the HSC redox system, 
however, the mechanism by which GSH cellular levels are regulated remains 
unclear (71, 77). 
Multidrug resistant protein 1 (MRP1/ABCC1) is an ATP binding cassette 
(ABC) transporter that effluxes a broad range of substrates, including both 
reduced and oxidized GSH (19, 78, 79). MRP1-mediated efflux of GSH is an 
important mechanism of ROS regulation in a variety of cell types (80, 81). MRP1 
is expressed at high levels in embryonic stem cells (ESCs), HSCs, bone marrow 
mononuclear cells (BMMC) and erythrocytes (82, 83) and deletion of MRP1 in 
mice increases endothelial progenitor cell function and differentiation due to loss 
of MRP1-mediated GSH efflux, increased GSH levels, and decreased ROS (81).  
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Interestingly, MRP1 expression is higher in HSCs as compared to mature blood 
cells suggesting a role for MRP1 in regulating hematopoiesis(84).  
In the current study, we show that MRP1 plays a role in regulating HSC 
self-renewal. Deletion of MRP1 in mice results in increased HSC frequency and 
increased HSC self-renewal.  The increase in HSC frequency and self-renewal is 
the result of decreased ROS levels due to the loss of MRP1-dependent GSH 
efflux. Additional evidence to support this mechanism comes from studies in 
which we treat normal mice with the GSH mimetic, N-acetyl-L-cysteine (NAC), 
which has been shown to increase HSC self-renewal properties (48, 85).  NAC 
treatment of C57BL/6 MRP1+/+ mice results in a phenotype that closely 
resembles that of C57BL/6 MRP1-/- mice, strongly suggesting that, indeed, 
increased HSC frequency and self-renewal in C57BL/6 MRP1-/- mice is the result 
of decreased ROS.  Finally, we have evidence that suggests that the down-
stream mechanism by which MRP1 regulates HSC self-renewal via GSH and 
ROS modulation is in part through the p38 MAPK pathway. 
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Methods: 
Animals: 
C57BL/6MRP1+/+ CD45.2 (MRP1+/+), C57BL/6 MRP1-/- CD45.2 (MRP1-/-) 
(generous gifts from Dr. Mary Vore’s laboratory, the University of Kentucky), and 
B6.SJL-Ptprca Pepcb/BoyJ MRP1+/+ CD 45.1 (MRP1+/+ CD45.1) mice (The 
Jackson Laboratories, Bar Harbor, ME) were maintained in the Division of 
Laboratory Animal Resources facility and were provided food and water ad 
libitum. B6.SJL-Ptprca Pepcb/BoyJ mice were utilized in the transplants. All 
assays utilized the C57BL/6 strain of mice. All mice were 8-12 weeks of age at 
the time of use.  The Institutional Animal Care and Use Committee of the 
University of Kentucky approved all experiments. Transplantation recipient mice 
in competitive repopulation experiments were provided special water containing 
antibiotics (sulfamethoxazole 0.8mg/ml and trimethoprim 0.16mg/ml) 1 week 
prior to irradiation.  During NAC treatment studies, mice were provided with 
5mg/mL NAC in their drinking water for four weeks.   
Flow Cytometry Analysis of Bone Marrow and Peripheral Blood 
HSC and progenitor cell analysis was carried out as previously described (86, 
87).  Briefly, donor mice were sacrificed and bone marrow (BM) was harvested 
from the tibias and femurs.  BM cells were suspended in phosphate buffered 
saline(PBS) containing 2% fetal bovine serum (FBS) (Life Technologies, 
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Carlsbad, CA) and subjected to red cell lysis with 0.15 M ammonium chloride 
solution with 0.1M sodium bicarbonate to enrich for mononuclear blood cells 
(MNBCs).  MNBCs were stained with APC-Cy 7-conjugated lineage markers 
(CD45R, CD11b, CD45R/B220, CD19, CD3e, TER119) and stem cell–specific 
markers, PE-CY7 conjugated Ly6A/7 (Sca-1), PerCP-Cy 5.5 conjugated CD117 
(c-Kit), PE conjugated CD135 (Flt-3), and FITC conjugated CD34. Stem cell cells 
were stained with PE-conjugated rat anti-mouse 135, Alexa Fluor 647-conjugated 
rat anti-mouse CD150  and FITC-conjugated rat anti-mouse CD34. Cell viability 
was assessed using the exclusion dyes DAPI and propidium iodide (PI)  
(5 μg/ml).  Alternatively, peripheral blood (PB) was taken from the submandibular 
vein of mice and collected in a 1mL EDTA containing blood collection tube.  
Peripheral blood (PB) was lysed with red cell lysis buffer as described above and 
mononuclear blood cells (MNBCs) were collected.  PB MNBCs were 
subsequently stained for Lineage Marker analysis (FITC conjugated CD11b, 
PerCP-Cy5.5 conjugated CD19, V450 conjugated Gr1, PE conjugated Ter119, 
PE-Cy7 conjugated CD3e). All monoclonal antibodies were purchased from BD 
Biosciences (Franklin Lakes NJ). Flow cytometric analysis was carriedout in the 
University of Kentucky Flow Cytometry Core Facility on a BD LSRII (BD 
Biosciences, Franklin Lakes, NJ). For the DCF-DA assay Alexa Fluor 647-
conjugated rat anti-mouse CD150 was not used and Alexa Fluor 647-conjugated 
rat anti-mouse CD34 was used in place of FITC-conjugated rat anti-mouse 
CD34. For the monochlorobimane (MCB) assay 4’-6-diamidino-2-phenylindole 
(DAPI) was excluded due to overlap with MCB detection. 
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Peripheral Blood Analysis 
 
MRP1+/+ CD45.2 and MRP1-/- CD45.2 mice were bled via submandibular vein 
and 250 μL of blood was collected in a 1mL, EDTA containing, collection tube.  
Complete blood analysis was carried out using a Hemavet 950 FS (Drew 
Scientific Inc Oxford, Connecticut) and by flow cytometry as described above. 
 
Bromodeoxyuridine (BrdU) Assay  
 
The proliferative activity of MRP1+/+ CD45.2 and MRP1-/- CD45.2 HSCs was 
measured using the BrdU Assay Kit (BD Bioscience, Franklin Lakes, NJ). Mice 
were injected intraperitoneally (IP) with FITC-BrdU (1 mg per kg body weight).  
After 5 hours, mice were sacrificed and BM was collected for flow cytometric 
analysis as described above with modifications. Since fluorescein isothiocyanate 
(FITC) was utilized for BrdU detection, Alexa Fluor 647-conjugated rat anti-
mouse CD150 was not used and Alexa Fluor 647-conjugated rat anti-mouse 
CD34 was used in place of FITC-conjugated rat anti-mouse CD34. 
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Colony Forming Cell (CFC) Assay 
 
BM was obtained from MRP1+/+ CD45.2 and MRP1-/- CD45.2 mice as described 
above.  Enriched MNBCs were washed and resuspended in Iscove’s Modified 
Dulbecco’s Medium (IMDM) + 2% FBS to a concentration of 50,000 cells/mL. 
Next 0.3 mL of the resuspended cells was added to 3 mL of Methocult GF M3434 
media (Stem Cell Technologies, Vancouver, BC, Canada), vortexed and allowed 
to sit for 20 minutes.  Next, 1.1 mL of the mixture was added to a 35mm culture 
in duplicate. The duplicate 35 mm dishes were placed within a 100 mm dish 
containing a third uncovered 35 mm dish containing sterile water. Cells were 
allowed to grow for 8-12 days at 37° C and 5% CO2. After incubation, colonies 
were identified and counted under the microscope and scored as blast-forming 
units (BFUs), colony-forming units (CFUs), colony forming unit- granulocyte 
macrophage progenitor (CFU-GMs), or colony-forming unit granulocytes, 
erythrocyte, monocyte, megakaryocyte progenitors (CFU-GEMMs).  
 
Annexin V- Staining for Apoptosis 
 
The apoptotic activity of MRP1+/+ and MRP1-/- HSCs was measured using the 
Annexin V Assay Kit (BD Bioscience, Franklin Lakes, NJ). Briefly, HSCs were 
stained as previously described and additionally, cells were washed with binding 
buffer before staining with annexin V. Cells were washed and analyzed by 
fluorescence activated cell sorting (FACs). Since FITC was utilized for Annexin V 
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detection, Alexa Fluor 647-conjugated rat anti-mouse CD150 was excluded from 
the analysis to allow for Alexa Fluor 647-conjugated rat anti-mouse CD34 in 
place of FITC-conjugated rat anti-mouse CD34. 
 
Transplantations: 
 
Limiting-dilution competitive repopulation assays were carried-out to determine 
HSC frequency as previously described (86).  Briefly graded numbers (10,000, 
20,000 and 60,000 chosen based on previous studies) of test cells (MRP1+/+ or 
MRP1-/- MNBCs) were admixed with 200,000 competitor cells (MRP1+/+ CD45.1 
MNBCs) and injected intravenously into lethally irradiated (total dose 9 Gy) 
MRP1+/+ CD45.1 recipient mice(86). Blood was collected from recipient mice via 
submandibular cheek bleeds at 4, 8, 12, and 16 weeks post transplantation and 
subject to linear marker analysis (B cells (PerCP-Cy5.5 CD19), T lymphocytes 
(PE-Cy7 conjugated CD3e), granulocytes (V450 conjugated (Ly6G/Ly6C), and 
macrophages (APC-CY7 conjugated CD11b)). Additionally, APC conjugated 
monoclonal anti-CD45.2 and PE conjugated anti-CD45.1 stains were used to 
identify the origin of the cells. For serial transplantation studies to study ability of 
HSCs to repopulate the bone marrow (BM), 1 million test cells (MRP1+/+ or 
MRP1-/- MNBCs) were admixed with 1 million competitor cells (MRP1+/+ CD45.1 
MNBCs) and injected intravenously into lethally irradiated (total dose 9 Gy) 
MRP1+/+ CD45.1 recipient mice.  After 16 weeks blood and bone marrow were 
extracted for analysis. Additionally, 1 million whole BM cells from each primary 
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mouse were injected into a matched lethally irradiated (total dose 9Gy) MRP1+/+ 
CD45.1 recipient mice. Blood and BM were analyzed again after 16 weeks.   
 
DCF-DA: 
 
MNBCs were enriched from MRP1+/+ and MRP1-/- C57BL/6 mouse BM and 
stained for HSC (LSK) analysis as described above in flow cytometry analysis of 
bone marrow and peripheral blood.  After a 60 min incubation on ice, the cells 
were washed and resuspended in 100 μL RPMI1640/10%FBS in the presence of 
50 μM MK571 (Cayman Chemical Company, Ann Arbor, MI), an MRP1 inhibitor. 
Cells were washed and resuspended in RPMI1640/10%FBS with 50 μM MK571 
and DCF-DA to stain for levels of ROS (Sigma Aldrich, Saint Louis, MO)  (1:5000 
dilution using 25mM stock) for 10-15 min at 37° C. Cells were washed and 
resuspended in PBS containing 2% FBS containing MK571 and analyzed by flow 
cytometry as previously described.  
 
Monochlorobimane: 
MNBCs were enriched from MRP1+/+ and MRP1-/- C57BL/6 mouse BM and 
stained for HSC (LSK) analysis as described above in flow cytometry analysis of 
bone marrow and peripheral bloodl.  After a 60 minute incubation on ice, the cells 
were washed and resuspended in 100 μL RPMI1640/10%FBS and incubated 
with 50 μM MK571 (Cayman Chemical Company, Ann Arbor, MI) an MRP1 
inhibitor. Cells were washed and resuspended in RPMI1640/10%FBS with 50 μM 
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MK571 and subsequently incubated with monochlorobimane, which has high 
affinity for glutathione, but will also bind to other thiols (MCB, EMD Millipore, 
Merck KGaA, Darmstadt, Germany) (10 μM) 20 min 37° C. Cells were washed 
and resuspended in PBS containing 2% FBS and MK571. Cells were then 
analyzed by flow cytometry as previously described. 
 . 
Statistics: 
Unless otherwise noted, mean fluorescence was extrapolated from flow 
cytometry analysis using FlowJo software (Tree Star Inc., Ashland, OR USA) and 
plotted graphically with a minimum of n=3. Statistical analysis was performed in 
Prism software (GraphPad, LaJolla, CA USA) (student t-test). 
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Results: 
Deletion of MRP1 increases HSCs, B Cells and T Cells in Mice 
It has been established that ABC transporters, mainly ABCG2, play an 
important role in the regulation of HSC self-renewal and differentiation (88). 
Therefore, it is reasonable to speculate that other ABC transporters, such as 
MRP1, could play a similar role. To investigate the possibility that MRP1 might 
regulate HSC self-renewal and/or differentiation, we enriched BM MNBCs from 
MRP1+/+ and MRP1-/- C57BL/6 mice and determined their HSC content by flow-
cytometry as described in the Methods (Figure 2.2, flow cytometry gating shown 
in Figure 2.1).  Our analysis revealed that MRP1-/- mice have a significant 
increase in each subpopulation of HSCs (long-term HSCs (LT-HSCs), short-term 
HSCs (ST-HSCs), and multipotent progenitors (MPPs)) as compared to MRP1+/+ 
mice (Figure 2.2A). In addition, we determined BM progenitor content and found 
that MRP1-/- mice have increased numbers of megakaryocyte erythroid 
progenitors (MEPs) (Figure 2.2B). 
To determine how the increased number of HSCs in the MRP1-/- mice 
impacts overall hematopoiesis, we analyzed the peripheral blood (PB) of both the 
MRP1+/+ and MRP1-/- C57BL/6 mice for progenitor and fully differentiated blood 
cell subtypes by flow cytometry (Figure 2.2C) and hemavet (Table 2.1), 
determined the ability of BM derived MNBCs to give rise to more differentiated 
blood types by colony forming cell (CFC) assay (Figure 2.2D), and determined 
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HSC proliferation (Figure 2.2E).  Flow cytometry analysis revealed that MRP1-/- 
mice have more CD19 (B cells), CD3e (T cells), and Gr1 (macrophages, natural 
killer (NK) cells, eosinophils, monocytes and neutrophils) marked cells as 
compared to the MRP1+/+ mice (Figure 2.2C). Interestingly, no difference was 
seen with CD11b, which marks macrophages and NK cells, suggesting the 
differences seen in Gr-1 marked cells is due to eosinophils, monocytes, and 
neutrophils.   Based on our BM studies, we reasoned that an increase in HSCs 
would correlate with an increase in the number of differentiated colonies 
measured by CFC assay however, this was not the case. CFC assay analysis 
showed that the number of BFU-E, CFU-E, CFU-GM, and CFU-GEMM colonies 
formed from BM derived from MRP1-/- MNBCs was all decreased as compared to 
the MRP1+/+ mice (Figure 2.2D). Although this seemed contradictory, it is likely 
due to the decreased proliferation of the MRP1-/- mouse derived HSCs (Figure 
2.2E and 2.3).  Analysis of HSC proliferation by BrdU staining (Figure 2.2E 
(Flow Cytometry shown in Figure 2.3)) showed that the HSCs derived from the 
MRP1-/- mice are replicating more slowly (Figure 2.2E) than those from 
MRP1+/+mice. Cells in the G0 phase of the cell cycle are dormant/quiescent and 
the G1 phase proceeds S phase where replication is starting to occur. S phase of 
the cell cycle is when DNA replication occurs. An increase in the cells in G0/G1 
and decrease in S phase would signify less/slower replication is taking place. 
Analysis of apoptosis by annexin V staining in HSCs derived from MRP1+/+ mice 
and MRP1-/- C57BL/6 mice showed no difference (Figure 2.4).  Hemavet 
analysis, a full blood panel, showed no major differences except strikingly, 
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MRP1-/- mice have double the number of platelets. Considering that MRP1-/- mice 
have no adverse effects related to their physiology, viability, or fertility unless 
stressed, it is not surprising that the hemavet analysis of fully differentiated cells 
in the blood did not reveal any differences, other than a doubling of the platelets.  
However, it is reasonable to postulate that differences in the blood, other than 
platelets, could arise under stressed conditions, such as, exposure to toxins 
and/or naturally occurring carcinogens (21). Increased cellular stress has been 
known to play a role in a variety of diseases such as cancer, cardiovascular 
disease and aging.  
 
HSCs express MRP1 and MRP4 differentially 
 
MRP1 and MRP4 have overlapping substrates and are ubiquitously 
expressed in a variety of tissues, including HSCs, in both mice and humans (3, 4, 
6, 21, 89, 90). Based on these findings, it is reasonable to postulate that MRP4 
may compensate for deletion of MRP1 in HSCs.  Therefore, we determined 
MRP4 expression levels in the MRP1+/+ and MRP1-/- C57BL/6 mice HSCs 
(Figure 2.5B). Additionally, we determined the expression levels of MRP1 in 
HSCs from MRP1+/+ C57BL/6 mice to establish a baseline for MRP1 expression 
in HSCs (Figure 2.5A). Using flow cytometry as described in the Methods, we 
found that all HSC subtypes in MRP1+/+ mice express MRP1, however ST-HSC 
and MPPs express significantly more MRP1 as compared to LT-HSCs (Figure 
2.5A).  Conversely, MRP4 expression was constant across all three HSC 
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subtypes in MRP1+/+ mice and MRP4 expression did not change upon deletion of 
MRP1 (Figure 2.5B). These results suggest that MRP4 does not compensate for 
the loss of MRP1, and therefore is not contributing to the overall increase in the 
number of HSCs found in the MRP1-/- mouse.  
  
Deletion of MRP1 increases HSC self-renewal capacity. 
 
To better understand the effect that the increased number of HSCs in the 
MRP1-/- mouse could have on hematopoiesis, we carried out a competitive 
limiting dilution assay (Figure 2.6) and a competitive serial repopulation assay 
(Figure 2.7).  The competitive limiting dilution assay utilized MNBCs from the 
C57BL/6 MRP1+/+ CD45.2 and MRP1-/- CD45.2 mice as the test cells and 
MNBCs from B6.SJL-Ptprca Pepcb/BoyJ MRP1+/+ CD45.1 mice as 
competitor/donor cells, and was carried-out as described in the Methods (Figure 
2.6).  Our studies showed that the total CD45.2 content in the transplanted mice 
was higher in mice transplanted with MRP1-/- MNBCs and increased with time at 
all three dilutions tested, with the most pronounced effect at the 60,000 dilution 
(Figure 2.6).  Competitive repopulation unit (CRU) values were calculated from 
week 16 blood samples to determine HSC frequency by scoring for all blood 
samples either positive or negative with regard to successful competitive growth 
of test cells, a positive score was given if all four blood cell types had 5% or 
greater CD45.2 cells.   The frequencies of long-term HSCs were calculated from 
the proportions of negative recipients in each cell dose group using L-Calc 
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software (Figure 2.6B-D).  Our analysis revealed that MRP1-/-MNBCs gave rise 
to higher frequency of CD45.2 cells in our transplants as compared to MRP1+/+ 
MNBCs, as shown by visual inspection and statistical analysis of flow data 
(Figure 2.6B-D).  These differences were statistically significant and resulted in 
calculated CRU values of a HSC frequency of 1/87,163 for MRP1+/+ CD45.2 
mouse MNBCs and a HSC frequency of 1/18,073 for MRP1-/- CD45.2 mouse 
MNBCs, with 95% confidence interval of (50,061 – 281,839) and (13,006 – 
48,844) respectively after 16 weeks.  
Taken together, our competitive limiting dilution assay and phenotypic 
analysis of  C57BL/6 MRP1+/+ and MRP1-/- mice suggested that deletion of MRP1 
increases the number of HSCs via increased self-renewal.  To test this model we 
conducted a competitive serial transplantation assay. After 16 weeks post-
transplant the CD45.2 content was analyzed, decompiled, and graphed for 
comparative purposes in Figure 2.7A. Figure 2.7A shows that the secondary 
recipients transplanted with MRP1-/- MNBCs have a significantly higher 
percentage of CD45.2 cells as compared to secondary recipients receiving 
MRP1+/+ MNBCs. This data was further broken down into BM total lymphocytes 
(Figure 2.7B), LSKs (HSCs) in BM (Figure 2.7C), and peripheral blood (PB) 
(Figure 2.7D) for both primary and secondary transplants.  The results of the 
competitive serial transplant assay strongly support the hypothesis that deletion 
of MRP1 increases the HSC self-renewal capacity.  
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 Deletion of MRP1 increases HSC self-renewal via increased GSH and 
decreased ROS in the cell. 
 
MRP1-mediated regulation of cellular ROS plays an important role in 
regulating redox gene expression and oxidative stress signaling pathways (81, 
91-94). Additionally, studies have shown that this regulation occurs via MRP1-
dependent efflux of GSH (94-96). Based upon these studies we hypothesized 
that deletion of MRP1 increases HSC self-renewal by decreasing cellular ROS 
due to the loss of MRP1-mediated GSH efflux.  Therefore, we compared the 
cellular levels of GSH (Figure 2.8A) and ROS (Figure 2.8B) in HSCs from 
C57BL/6 MRP1+/+ and MRP1-/- mice. To measure GSH levels we utilized the 
MCB assay, a standard flow based assay that measures relative GSH content. 
Our analysis of HSCs from C57BL/6 MRP1+/+ and the MRP1-/-mice revealed that 
deletion of MRP1 significantly increases cellular GSH levels (Figure 2.8A).  If our 
hypothesis is correct, then increased GSH, an antioxidant that directly scavenges 
ROS, should decrease cellular ROS.  To examine the cellular ROS levels we 
utilized 2’-7’-dichlorodihydrofluroscein diacetate (DCF-DA), a stain that measures 
the redox state of the cell. Previous studies using DCF-DA have found that low 
DCF-DA populations have the self-renewing, quiescent characteristics of HSCs 
found in the HSC niche (48). Our analysis of HSCs from C57BL/6 MRP1+/+ and 
MRP1-/- mice revealed that deletion of MRP1 decreased cellular DCF-DA in 
every subpopulation of HSCs (Figure 2.8B) indicating a decrease in cellular 
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ROS. The data from the DCF-DA and MCB assays were in agreement and 
support our hypothesis that deletion of MRP1 increases HSC self-renewal via 
decreased ROS levels from loss of MRP1-mediated GSH efflux.  
 
Deletion of MRP1 alters the expression of redox response genes and p38 
MAPK activity. 
  
 ROS levels are tightly regulated and changes are associated with altered 
expression levels of redox response genes.  Therefore, it is likely that the 
increase in cellular GSH and decrease in cellular ROS that we see in C57BL/6 
MRP1-/- HSCs alters the expression profile of a number of redox response genes.  
To investigate this possibility, we measured the expression of a number of redox 
response genes in HSCs, specifically in LT-HSC, ST-HSC, and MPPs in 
C57BL/6 MRP1+/+ and MRP1-/- mice by flow cytometry (glutamate-cysteine ligase 
modifier subunit (GCLM) and glutamate-cysteine ligase catalytic subunit (GCLC), 
glutathione reductase (GSR), superoxide dismutase (SOD1 and SOD2), catalase 
(CAT), and glutathione peroxidase (Gpx)) (Figure 2.8C).  Our analysis revealed 
a number of interesting changes.  Deletion of MRP1 significantly reduced the 
expression of glutamate-cysteine ligase, modifier subunit (GCLM) and increased 
the catalase (CAT) expression in LT-HSCs.  Furthermore, expression of GSR 
was significantly increased in all HSC subtypes, LT-HSCs, ST-HSCs, and 
multipotent progenitors (MPPs). It is important to note that the expression of 
GCLM and GCLC are closely linked as they form a stable heterodimer, which is 
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required for the first step in GSH synthesis, the conjugation of glutamate and 
cysteine. Since less GSH would be synthesized with decreased GCLC and 
GCLM, the increased glutathione is most likely the result of increased GSH 
recycling.  
ROS and the activity of the p38 MAPK pathway in stem cells are closely 
linked (50, 97, 98).  Upon increase of cellular ROS, p38 is activated by dual 
phosphorylation at the Thr180/Tyr182 residues (99-101). To evaluate if p38 
phosphorylation was decreased by the deletion of MRP1, we analyzed the 
expression and phosphorylation status of p38 in C57BL/6 MRP1+/+ and MRP1-/- 
HSCs (Figure 2.8D). Our hypothesis, if true, would anticipate a decrease in 
phosphorylation at Thr180/Tyr182.  Indeed, our analysis revealed that p38 
phosphorylation at Thr180/Tyr182 was significantly decreased in LT-HSCs 
MRP1-/- mice as compared to MRP1+/+ mice.  It is important to note that although 
the decrease in p38 phosphorylation was not of significance in ST-HSCs and 
MPPs, both subpopulations were significant by student t-test, with p values of 
0.03 and 0.04 respectively before applying a Holm-Sidak correction for multiple 
comparisons, where the values became non-significant.  Our results imply that 
deletion of MRP1 lowers cellular ROS by increasing cellular GSH, and the 
decreased cellular ROS alters the expression of several ROS response genes 
and importantly, downregulates the p38 MAPK pathway. These results strongly 
support our model that deletion of MRP1 increases HSC self-renewal via 
increasing cellular GSH, which decreases cellular ROS.  Further, these results 
suggest two potential mechanisms (redox response gene expression and p38 
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signaling) by which deletion of MRP1 increases HSC self-renewal. Our results 
are in agreement with previous research finding that increased ROS in stem cells 
typically act through the p38 MAPK pathway to limit the lifespan of HSCs (50). 
These studies found that increased ROS would activate HSC specific 
phosphorylation of p38 MAPK, which decreased HSC quiescence(50). They 
could also rescue this ROS induced activation of p38 MAPK by using an inhibitor 
for p38 MAPK (50). 
 
NAC treatment can recapitulate MRP1-/- phenotype in WT 
  
Treatment of mice with NAC was shown to increase HSC quiescence and 
rescue a “normal” HSC phenotype in mice with a genetic deletion that results in 
increased HSC ROS (102). Treatment of cells with NAC stimulates glutathione 
synthesis, by providing cysteine, and upon entering the cells, NAC can act as a 
strong cellular antioxidant on its own (55). Based upon these findings, we 
hypothesized that if our model is true that the increase in HSC self-renewal in the 
C57BL/6 MRP1-/- mice is the result of decreased ROS due to increased cellular 
GSH, then treatment of MRP1+/+  mice with NAC should result in HSCs that are 
phenotypically similar to HSCs derived from the MRP1-/- mice.  To test this 
hypothesis as a proof of principle, we administered NAC treated water to 
C57BL/6  MRP1+/+ mice over 4 weeks and subsequently carried out a complete 
BM and PB analysis (Figure 2.9A and B) and determine GSH and ROS levels in 
the mouse HSCs (Figure 2.9C and D).  Our experiments revealed that after 4 
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weeks of NAC treatment, there were significantly more LT-HSCs and ST-HSCs 
in the NAC treated MRP1+/+ mice as compared to non-NAC treated (Figure 
2.9A).  Contrary to our findings in the BM, 4 weeks of NAC treatment had no 
effect on progenitors in the PB (Figure 2.9B). This is not entirely surprising, as it 
takes 16 weeks to completely repopulate the progenitors and fully differentiate 
cells in the blood.  NAC treatment did, however, significantly reduce HSC ROS 
(Figure 2.9D). Surprisingly, the MCB assay revealed that GSH was reduced in 
the NAC treated mice as compared to the non-treated MRP1+/+ mice (Figure 
2.9C).  Overall, the results of the NAC study supports our model that deletion of 
MRP1 increases HSC self-renewal by increasing cellular GSH that in turn 
reduces cellular ROS.  The reduction of cellular ROS then signals changes in 
redox response gene expression and reduces p38 MAPK activity and signaling.  
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Discussion 
In the current study we present data that strongly suggest a role for MRP1 
in regulating HSC self-renewal.  The key findings of our study are that deletion of 
MRP1 in mice results in increased cellular GSH, due to loss of MRP1-mediated 
GSH efflux. The increased levels of the antioxidant GSH resulted in a decrease 
in cellular ROS, which in turn, signals changes in the expression of redox 
response genes and decreases p38 signaling. Due to the decreased efflux of 
GSH, GSH levels are increased. GCLC and GCLM were downregulated while 
GSR was upregulated with the increased GSH levels. This is mostly likely due to 
GSH being recycled and not additional GSH being synthesized. These findings 
are supported by our experiments in which mice were supplemented with NAC, 
which showed that treatment of MRP1+/+ mice with NAC increases primitive 
HSCs and reduces HSC ROS similar to that seen in HSCs from MRP1-/- mice. 
Interestingly, NAC decreased the levels of GSH while still decreasing ROS. We 
reasoned this is most likely due to NAC being able to scavenge ROS on its own, 
and doesn’t necessarily have to donate a cysteine to stimulate GSH synthesis.  
Together all our studies presented here strongly support our proposed model 
(Figure 2.10). To our knowledge the data presented in this paper are the first to 
demonstrate that lack of MRP1 can increase HSC frequency and self-renewal, 
and suggests that downregulation of MRP1 function and/or expression by the cell 
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or pharmaceutically will increase HSC self-renewal.  Potential implications of our 
findings are that by increasing cellular GSH with use of MRP1 inhibitors or use of 
GSH synthesis inducers will enhance therapeutic uses of HSCs for bone marrow 
failure, bone marrow transplants, and treatments for leukemia (71). 
While this is the first study to indicate that lack of MRP1 can decrease the 
amount of ROS present in the HSCs, there have been several studies in HSCs 
and the importance of low ROS for self-renewal and ability to transplant in the 
long term, where increased levels of ROS altered the quiescent state of HSCs 
and their ability to self-renew(47, 71)(48, 103).  Further support for MRP1 
regulating cellular ROS via GSH efflux has clearly been established for 
maintenance of neurons and protection of cardiomyocytes (80, 94, 104, 105). To 
date, there have been only a small number of studies that have mentioned a 
possible role for GSH in regulation HSC self-renewal and differentiation. 
However, there was a recent study using gastrointestinal cancer stem cells that 
showed CD44v (glycoprotein correlated with tumors and metastatic potential)-
mediated changes in GSH directly alter cellular levels of ROS and ROS-
activation of the p38MAPK pathway (97).This study showed that CD44v could 
control the levels of reduced GSH, where increased levels of CD44v showed 
enhanced GSH synthesis (97) . This enhanced GSH in turn decreased ROS 
levels and downstream targets of ROS, such as p38MAPK (97). Downregulation 
of p38 MAPK has been shown to increase the cellular growth in cancer cells (97). 
In the present study we provide strong evidence that supports a similar role in 
HSCs.  
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HSCs from our MRP1-/- mouse appear to differentiate preferentially 
towards megakaryocyte erythroid progenitors (MEPs) and platelets. A recent 
study has found that loss of self-renewal is not required for differentiation to 
occur, especially with regards to megakaryocyte progenitors (106). This supports 
our finding that MRP1-/- HSCs occur in both a higher frequency and with a 
greater self-renewal capacity, and the finding that deletion of MRP1results in an 
increase in MEPs in the PB.  Interestingly, MRP4 is preferentially expressed in 
progenitors and fully differentiated cells, especially megakaryocytes and platelets 
(107).  In our studies we found that MRP4 expression is similar in LT-HSCs, ST-
HSCs, and MPPs in both MRP1-/- and MRP1+/+ mice; however, we cannot rule 
out the possibility that MRP4 is influencing progenitor differentiation beyond early 
HSC differentiation to MPPs in the absence of MRP1 with our current analysis.  
In our study we found that several redox proteins were altered in our 
MRP1-/- mouse. With an increase in glutathione and decrease in ROS we also 
saw a significant decrease in GCLM, while we saw a significant increase in both 
glutathione reductase and catalase. Due to the fact that GCLM is downregulated 
and glutathione reductase is upregulated it is reasonable to conclude that 
glutathione is being recycled and not synthesized in the absence of MRP1. It is 
also important to note that DCF-DA is a non-specific stain for ROS, and thus we 
could not conclude which type of ROS was present in our MRP1-/- mice.  
 Interestingly, HSCs derived from MRP1-/- mice have a similar redox profile 
to hepatic stellate cells, which are found to be derived from HSCs during liver 
injury (108). Greater glutathione and decreased catalase is found upon hepatic 
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stellate cell proliferation/activation out of a quiescent state (108). Similarly, our 
HSCs show low levels of glutathione in the LT-HSCs, with increasing levels in the 
ST-HSCs and MPPs. Further, the MRP1-/- mouse has increased catalase in only 
the LT-HSCs, with significantly lower catalase levels in ST-HSCs and MPPs 
(Figure 2.8C). In hepatic stellate cells, catalase and not glutathione, is required 
to protect against oxidative stress induced apoptosis (108). In the hepatic stellate 
cell study  they found that inhibition of glutathione increased  necrosis in both the  
absence and presence of exogenous hydrogen peroxide (108). Additionally, 
inhibition of catalase and glutathione peroxidase increased apoptosis in both the 
absence and presence of exogenous hydrogen peroxide (108). Since both 
catalase and glutathione can scavenge hydrogen peroxide it would seem 
counterintuitive for both to upregulated in LT-HSCs; however, dual upregulation 
of both glutathione and catalase have been seen in other studies (109).  
Interestingly, a study found that NAC treatment, which can scavenge ROS on its 
own and stimulate glutathione synthesis, would stimulate the upregulation of 
catalase (109).  Therefore it is possible that catalase levels are increased in LT-
HSCs derived from the MRP1-/- mice to protect LT-HSCs from apoptosis when 
glutathione synthesis is altered. Support for this comes from our finding that there 
is no difference in HSC apoptosis between MRP1-/- and MRP1+/+ mice. The 
model in which catalase is the main protector against apoptosis, and not 
glutathione, in HSCs warrants further investigation. 
A very recent study has found that when glutathione metabolism is altered 
it will impact the expression of other antioxidants, such as catalase (110). This 
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study, like ours, found that GCLM and GCLC were expressed at relatively low 
levels in hematopoietic stem cells (110). Additionally they found increased GCLM 
and GCLC expression in the leukemic stem cells (110). Interestingly, as the stem 
cells become leukemic catalase expression became downregulated (110). 
Our data, suggests a role for glutathione in regulating cell growth 
independent of apoptosis.  This model is supported by our findings in the colony 
forming cell assay (Figure 2.2E) that there was an unexpected decrease in our 
differentiated colonies that could not be attributed to apoptosis but rather as the 
result of decreased cell growth of the MRP1-/- mouse HSCs. 
Our hypothesis is further supported by our NAC studies that showed that 
treatment of normal MRP1+/+ mice with NAC would result in an MRP1-/- like 
phenotype in the HSCs. We utilized NAC to decrease the ROS present in 
MRP1+/+ mice in an attempt to recapitulate the MRP1-/- HSC phenotype. We 
found that after 4 weeks of NAC treatment the amount of LT and ST-HSCs was 
increased. Such a finding strongly suggests that indeed in the MRP1-/- mouse, 
HSC self-renewal is increased by the reduced cellular levels of ROS that result 
from the loss of MRP1-mediated GSH efflux and subsequent rise in cellular GSH. 
It is important to note that we saw a significant decrease in the amount of GSH 
following NAC administration. We reason that this is due to either NAC 
scavenging ROS on its own, forming NAC-disulfide products, or a mechanism 
similar to buthionine sulfoxide (BSO) in conjunction with NAC administration 
showing decreased GSH (111, 112). BSO alters glutathione synthesis by 
inhibiting γ-glutamylcysteine synthetase so glutathione isn’t synthesized (111). If 
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we truly recreated our MRP1-/- phenotype we would anticipate that increased 
glutathione would also downregulate glutathione synthesis. Alternatively, NAC 
treatment was found to increase levels of H2O2 in some cells and decrease 
glutathione levels(113). Pertinent to our study, treatment of mice with NAC was 
found to restore HSC self-renewal, through what is believed to be a p38 MAPK-
dependent pathway (48).  Overall the data in our current study establishes MRP1 
as a regulator of self-renewal and differentiation in HSCs.  
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 Figure 2.1 
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 Figure 2.1: MRP1+/+ and MRP1-/- Flow Cytometry Analysis of BM 
Flow-cytometric analysis of MNBC’s derived from MRP1+/+ and MRP1-/- mice BM 
for HSC content. Bone marrow extractions were performed on MRP1-/- and 
MRP1+/+ mice as described in methods. Enriched MNBCs were stained and 
analyzed for HSC content as described in methods.  MRP1+/+ and MRP1-/- 
lymphocytes, negative for lineage markers, were further separated by c-Kit and 
Sca1 expression (LSK cells, representing the HSCs) (A and C).  Cells expressing 
both c-Kit and Sca1 were selected and further analyzed for CD34 and Flt3 
expression (B and D).  Here, CD34- and Flt3- cells represent LT-HSCs, CD34+ 
and Flt3- represent ST-HSCs, and CD34+ and Flt3+ cells represent MPPs. Flow 
data shown here are representative of all samples analyzed for each mouse 
type. (n=3) 
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Figure 2.2 
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Figure 2.2 MRP1-/-mice have more HSCs than MRP1+/+. Bone marrow 
extractions were performed on MRP1-/- and MRP1+/+ mice. Flow cytometric 
analysis of MNBCs derived from MRP1+/+ and MRP1-/- mice BM for HSC content 
(A) and BM progenitor content (B); peripheral blood (PB) for progenitors content 
(C). Colony forming cell (CFC) assays were carried-out with BM derived MNBCs 
from MRP1+/+ and MRP1-/- mice to determine ability of progenitors to give rise to 
differentiated blood cells (D). Microscopy was used to identify visually distinct 
colonies (E). BrdU analysis of BM-derived HSCs from MRP1+/+ and MRP1-/- mice 
were carried out as described in methods. In brief, mice were treated with BrdU 
by IP injection 5 hours prior to harvesting bone marrow for analysis by flow 
cytometry. 10,000,000 cells were collected for each sample run on flow 
cytometry. All graphs are comprised of data from at least n=3 mice. Each bar 
represents the mean + S.E.M. *p<0.05; **p<0.01; ***p<0.001 vs. control 
(MRP1+/+). 
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Figure 2.3 
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Figure 2.3 HSC proliferation was measured by flow cytometry via BrdU 
assay. MRP1+/+ and MRP1-/- mice were analyzed by BrdU staining for cellular 
 proliferation from MNBCs.  Mice were injected by IP with BrdU as described in 
methods.  After a 5 hours, MNBCs derived from MRP1+/+ and MRP1-/- BM were 
subjected to staining and flow cytometric analysis as described in methods. 
Upper panels depict the gating (selection) for HSCs in MRP1+/+ (left) and MRP1-/- 
(right) mice which is representative of LSK cell (Lyn- C-KIT+ SCA-1+) (A). BrdU 
fluorescence was then analyzed in LSK cells in histogram format to calculate the 
percent of cells in G0/1 and S phase for MRP1+/+ (left) and MRP1-/- (right) (lower 
panels). Data shown here are representative for all samples analyzed for each 
mouse type (n=3). 
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Figure 2.4. Analysis of apoptosis in MRP1+/+ and MRP1-/- mouse HSCs by 
Annexin V Apoptosis was analyzed in MRP1+/+ and MRP1-/- mouse derived 
HSCs by annexin V staining and flow cytometry as described above in methods. 
Annexin V has high affinity for phosphatidyl serine (PS), and can detect early 
stages of apoptosis where PS is being translocated.HSCs from MRP1+/+ (left) 
and MRP1-/- (right) show no differences in their Annexin V flow cytometry profiles.  
An increase in apoptosis would be marked by an increase in fluorescence of 
Annexin V in the upper right quadrant of histograms.  Data shown here are 
representative for all samples analyzed for each mouse type (n=3). 
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Table 2.1 Murine Whole Blood Analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Table 2.1. Data represented in the table is calculated from n=3 mice and 
includes standard error. Abbreviations used in table are for cell types white blood 
cells (WBC), neutrophil (NE), lymphocyte (Ly), monocyte (MO), eosinophil (EO), 
basophil (BA), red blood cell (RBC), hemoglobin (HB), hematocrit (HCT), mean 
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean 
corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), 
platelets (PLT), mean platelet volume (MPV). 
 
 
 
 
 
 
 
 
 MRP1+/+             MRP1-/-     
WBC K/μL 12.1 ± 3.78 11.4 ± 2.79 
NE# K/μL 3.68 ± 2.57 3.07 ± 1.43 
LY# K/μL 7.88 ± 2.51 7.73 ± 1.35 
MO# K/μL 0.385 ±0.2 0.395 ± 0.03 
EO# K/μL 0.098 ± 0.06 0.155 ± 0.13 
BA# K/μL 0.035 ± 0.02 0.058 ± 0.05 
       
NE% % 27.5 ± 12.9 25.4 ± 5.8 
LY% % 68.3 ± 13.2 68.2 ± 5.5 
MO% % 2.36 ±0.32 3.66 ± 0.56 
EO% % 0.72 ± 0.31 1.23 ± 0.88 
BA% % 0.27 ± 0.09 0.45 ± 0.38 
        
RBC M/μL 7.87 ± 2.18 10.4 ± 0.34 
HB g/dL 12.9 ± 2.08 15.0 ± 0.5 
HCT % 40.9 ±4.27 44.8 ± 1.8 
MCV fL 43.2 ± 0.94 43.2 ±1.03 
MCH Pg 17.9 ± 4.23 14.5 ± 0.25 
MCHC g/dL 34.5 ± 0.78 33.6 ± 0.57 
RDW % 17.5 ± 0.51 18.6 ± 0.30 
        
PLT K/μL 481 ± 195 890 ± 52.0 
MPV fL 5.37 ± 0.23 4.95 ± 0.1 
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Figure 2.5 
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Figure 2.5: MRP1 expression increases as HSCs become more 
differentiated while MRP4 does not change. MRP1 (A) and MRP4 (B) 
expression was measured in HSCs enriched from MNBC’s derived from MRP1+/+ 
and MRP1-/- mouse BM via flow cytometry and 5,000,000 cells were collected for 
each sample. All graphs are comprised of data from at least n=3 mice. Each bar 
represents the mean + S.E.M. *p<0.05; **p<0.01 vs. control. MRP1-/- mice were 
used as a negative control for MRP1 expression in MRP1 +/+ mice. MRP1 +/+ mice 
were the control for  MRP4 expression in MRP1-/- mice.  
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 Figure 2.6 
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Figure 2.6: Deletion of MRP1 increases HSC frequency in BM. Limiting-
dilution competitive repopulation assays were carried out as described in the 
methods. Transplants were carried out using 10K (B), 20K (C), and 60K (D) 
MNBC test cells from either MRP1+/+ CD45.2 or MRP1-/- CD45.2 mice and 
admixed with 200,000 competitor MNBC cells (MRP1+/+ CD45.1). Blood was 
extracted for analysis of CD45.2 test cell content of CD3e, CD11, CD19, and Gr1 
marked blood cells at four week intervals.  The results were used to calculate an 
overall frequency of HSCs (competitive repopulation unit (CRU)) after 16 weeks 
(A). Transplantations were scored for all blood samples and scored as positive or 
negative with the regard to successful competitive growth of test cells, a positive 
score was given if all four blood cell types had 5% or greater CD45.2 cells.   The 
frequencies of long-term HSCs were calculated from the proportions of negative 
recipients in each cell dose group using L-Calc software (StemCell Technologies, 
Vancouver, BC, Canada) (n=6). *p<0.05.  
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Figure 2.7 
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Figure 2.7: Deletion of MRP1 increases HSC self-renewal.  Serial 
transplantation studies were carried out as described in the methods. In brief, BM 
was extracted from recipient mice at 16-weeks post transplantation, and 
analyzed by flow cytometry for CD45.2 marked lymphocytes (B) and HSC (C) 
content in primary and secondary mice.  From the primary transplant mice, 1x106 
BM derived MNBCs were used for the secondary transplants. In addition to 
analyzing lymphocyte and HSC (LSK) CD45.2 percentiles, the percent of CD45.2 
present in PB was measured (D). 5,000,000 cells were collected for bone marrow 
and 1,000,000 counts were collected for blood for each mouse sample via flow 
cytometry. Each bar represents the mean + S.E.M. * p<0.05 vs. MRP1+/+l (n=6).  
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Figure 2.8 
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Figure 2.8 Deletion of MRP1 reduces intracellular ROS, increases GSH, and 
alters redox response gene expression. MNBCs derived from MRP1-/- and 
MRP1+/+ mouse BM were subjected to the MCB assay for intracellular GSH 
content (A) and the DCF-DA assay for intracellular ROS levels (B) as described 
in methods. Similarly, redox response gene expression is reported as relative 
fluorescence as measured by flow cytometry (C). MNBCs were derived from 
MRP1+/+ and MRP1-/-mouse BM and were also subjected to p38 expression and 
phospho-p38 analysis; results are reported as relative fluorescence as measured 
by flow cytometry (D). Expression studies were carried out as described in 
methods. A minimum 5,000,000 cells was collected for all flow cytometry 
analysis. Mk571, an inhibitor for MRP1, was utilized in MCB and DCF-DA assays 
due to the fact they are MRP1 substrates. All graphs are comprised of data from 
at least n=3 mice. Each bar represents the mean + S.E.M. *p<0.05; **p<0.01, ** 
*p<0.001 vs. MRP1+/+.  
. 
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Figure 2.9 
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Figure 2.9: Treatment of MRP1+/+ mice with NAC partially recapitulates 
MRP1-/-mouse phenotype.  MRP1+/+ mice were either treated with saline or 
NAC in the drinking water for 4 weeks as described in methods.  Flow cytometric 
analysis was subsequently used to determine the HSC content of BM (A), the 
percent composition of differentiated cells in the PB (B), the intracellular GSH 
content of HSCs in BM (C), and intracellular ROS levels in BM HSCs (D).  All 
experiments were done as described in methods.  A minimum of 1,000,000 cell 
counts were collected for PB and 5,000,000 cell counts were collected for BM 
analysis. Each bar represents the mean + S.E.M for n=3. * p<0.05vs. saline 
treated control.  
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Figure 2.10: Proposed model for MRP1-mediated regulation of HSC self-
renewal. GSH is a substrate for MRP1-mediated efflux.  Reduction of MRP1 
function and/or expression decreases MRP1-mediated GSH efflux which results 
in increased intracellular GSH and decreased intracellular ROS.  In addition, 
decreased intracellular ROS signals changes in redox response protein 
expression as well as decreases p38 activity via reducing p38 phosphorylation.  
This reduction in p38 activity ultimately leads to reduced MAPK signaling and 
decreased expression of a variety of cellular proteins sensitive to cellular redox 
state.  Of particular interest is the decrease in GCLM expression, a protein that 
forms a dimer with GCLC, which results in the formation of a holoenzyme that is 
directly responsible for the rate-limiting step in GSH synthesis.   An increase in 
GR, the protein responsible for GSH recycling, suggests that GSH is being 
recycled rather than synthesized. 
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Chapter 3 
Post-translation regulation MRP1 by CK2α 
Background 
The function of Ycf1p, the yeast MRP1 homolog, is regulated via 
phosphorylation within the L0 region at Ser251 of the N-terminal extension by 
Cka1p (yeast homolog to CK2α) during salt stress (Figure 3.1A) (64). Unlike 
MRP1, Ycf1p is localized to yeast vacuole membranes rather than the plasma 
membrane.  Ycf1p transports substrates, including GSH, into the vacuole where 
it is sequestered and ultimately broken down via gamma-glutamyl transpeptidase 
(GGT) (65). Phosphorylation of Ycf1p by Cka1p correlates with decreased ROS 
due to a decrease in Ycf1p-mediated sequestration of GSH into the yeast 
vacuole(65).  Ycf1p is about 42.5% identical to human MRP1 (114).  However, 
much of the shared identity is restricted to the cytoplasmic loops of the protein, 
while there is very little shared identity in the membrane spans.  Based on a very 
high degree of homology in the L0 region (Figure 3.1B), we hypothesized that 
human CK2α regulates MRP1 via a similar mechanism at a conserved putative 
phosphorylation site at Thr249.  
The serine/threonine protein kinase CK2 is made is made of two catalytic 
α and two regulatory β units (57). Interestingly, these subunits can be active on 
their own. It has been established that CK2 can phosphorylate ABC transporters, 
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such as ABCA1 and ABCB1/Pgp (59, 60). Increased protein expression of CK2 
is found in all cancers that have been studied, which make CK2 a target for 
therapeutic cancer treatments (58, 61). CK2 has gained interest as a “druggable” 
target for leukemia treatment due a small number of studies that have shown that 
CK2 inhibitors target leukemic stem cells selectively (62, 63).  
 Previously in our lab a knockdown of CK2α in MCF7-derived cells 
expressing MRP1 was created. MCF7 cells served as an ideal model to study 
MRP1 function due to their lack of MRP1 expression, unless altered.  Knockdown 
of CK2 resulted in increased sensitivity to a known MRP1 substrate,doxorubicin. 
(115). Additional substrates for MRP1, such as leukotriene C4 and estradiol-17β-
D-glucuronide , were found to have decreased transport during CK2α knockdown 
indicating that CK2α was impacting MRP1-mediated transport (115). Previously 
our lab found that the yeast homolog to CK2 could phosphorylate the yeast 
MRP1 homolog at Ser251. A semiconserved site in human MRP1 at Thr249 was 
studied to see if human CK2 could control its phosphorylation. Thr249  was 
mutated to an alanine (Thr249A), whichdecreased MRP1-mediated transport 
(115). Another mutation Thr249E, a phoshomimicking mutation, was found to 
increase the MRP1-mediated transport (115). From these studies it was 
concluded that CK2α was regulating MRP1 by phosphorylation at Thr249 (115). 
For proof of principle to these studies we wanted to look at the role of CK2α on 
MRP1-mediated transport in cancer cell lines that naturally express both MRP1 
and CK2α. . Since Dox sensitivity was altered in our lab's previous CK2 knock-
down of CK2α cell-line we wanted to see if inhibitors for both CK2α and MRP1 
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could alter Dox sensitivity in the cell lines that expressed both MRP1 and CK2α 
using Dox-accumulation assays. If our previous studies were correct that CK2α 
could regulate MRP1 function we would anticipate that inhibitors for CK2α 
inhibitors would decrease MRP1-mediated export in a similar fashion as MRP1 
inhibitors.  The results of our Dox-accumulation assays showed that treatment 
with inhibitors for CK2α and/or MRP1 resulted in increased MRP1-dependent 
sensitivity/accumulation of intracellular Dox in all human cell lines, H460, HeLa, 
and A549. The decrease in MRP1-dependent efflux of Dox is supported by our 
findings in Dox cytotoxicity assays.  In the Dox cytotoxicity assays we measured 
MRP1-dependent drug resistance in the presence and absence of CK2α 
inhibitors.  We found that pretreatment of cells with CK2 inhibitors decreased 
MRP1-mediated protection against Dox cytotoxicity. 
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Materials and Methods: 
Materials:  
CK2 and ABC transporter inhibitors: tetrabromobenzotriazole (TBBz) was 
purchased from Sigma-Aldrich (St. Louis, MO), MK571 from Cayman Chemicals 
(Ann Arbor, MI), and PSC883 and Fumitremorgin C (FTC) from Solvo 
Biotechnology (Budapest, Hungary).  DMEM, RPMI, F-12K, FBS, 
Penicillin/Streptomicin were purchased from Gibco/Invitrogen (Carlsbad, CA). 
Doxorubicin (Dox) was purchased from Calbiochem/ Merck KGaA (Darmstadt, 
Germany). PMSF and Pepstatin A were purchased from Sigma-Aldrich (St. 
Louis, MO). 
Cell Culture: 
A549 (a human lung adenocarcinoma epithelial cell line which was a gift 
from Dr. Rolf Craven University of Kentucky) and cultured in F-12K with 20% 
FBS and Pen/Strep. H460 and HeLa cells (a gift from Dr. Vivek Rangnekar 
University of Kentucky) and were cultured in RPMI media with 10% FBS and 
Pen/Strep, and DMEM with 10% FBS and Pen/Strep, respectively 
Immunoblotting: 
Standard Western blotting procedures were followed. Briefly, cells were lysed in 
the presence of protease and phosphatase inhibitors. Protein concentrations 
were determined by BCA assay (Thermo-Scientific/Pierce, Waltham, MA). Total 
protein (20 μg) was loaded onto a 10% SDS-Page gel for analysis. Proteins were 
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wet transferred to nitrocellulose membrane, blocked with 5% non-fat dry milk in 
TBST, and subsequently incubated with primary and secondary antibodies to 
detect MRP1, CK2α, ABCB1, or ABCG2(Santa Cruz Biotechnology, Santa Cruz, 
CA)Dox Accumulation Assay  
Cells were plated in appropriate media 24 hours prior to the assay, without 
antibiotics, at 3x105 cells/well in 24 well dishes. This cell plating density was 
empirically determined to result in roughly 90% cell confluency at the time of the 
assay (~ 24 hour incubation time). When 90% confluency was reached, cells 
were incubated with 50µM Dox for 1 h, followed by a 30 min efflux step without 
Dox. Where indicated, cells were pretreated with inhibitor 30 min to 1 h prior to 
the addition of Dox. Next, cells were washed with PBS, trypsinized, transferred to 
1.7ml Eppendorf tubes, centrifuged and lysed in 700µl of RIPA buffer. Next, 
200µl of lysate was then transferred to Optilux 96-well Microplates (BD Falcon) 
and fluorescence read by Synergy 2 Multi-mode Microplate Reader(BioTek 
Instruments, Inc.) with excitation filter wavelength 460/40 and emission 
wavelength 560/15.  
Cytotoxicity Assays. 
 MTT assays (3-(4,5 dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium 
bromide) were used to measure cytotoxicity when exposed to Dox. Cells were 
plated in 96 well plates at 5x104/well to ensure proper confluency 24 hours prior 
to the assay. The following day, cells were plated in fresh media, media for each 
cell type is listed in materials and methods, containing drug or vehicle and 
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incubated at 37°C under 5% CO2 for 72 hours. MTT solution in amount equal to 
10% of the culture volume was added to the final concentration of 0.5ug/ml and 
cells were returned to the incubator. After 3 hours media was removed, DMSO 
was added, and plates were shaken until all MTT crystals dissolved. Absorbance 
was read at 560nm with Titertek Multiskan MCC/340 plate reader 
(Thermolabsystems, Fisher Scientific).  
 
Statistics:  
 
Statistical analysis for Dox Accumulation assays were performed by ANOVA 
followed by Bonferroni correction for multiple comparisons. Statistical analysis for 
MTT assays were done by normalizing the baseline absorbance (with no drug) 
and using Graphpad Prism 5 to calculate the four parameter logistic nonlinear 
regression curves.  
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Results: 
Inhibition of CK2 in MRP1 expressing cancer cell lines decreases MRP1-
mediated Dox efflux and increases cytotoxicity. 
A549 and H460 non-small cell lung cancer (NSCLC), and HeLa cervical 
cancer cells were selected for our analysis based on their high levels of MRP1 
and CK2 expression. In addition, we determined the expression level of ABCB1 
and ABCG2, which have similar substrate specificities as MRP1.  The substrate 
overlap between MRP1, ABCB1, and ABCG2 includes Dox; therefore, 
assessment of ABCB1 and ABCG2 expression and their contribution to Dox 
accumulation and cytotoxicity is a critical component of our studies. Figure 3.2A 
shows that none of the chosen cell lines express ABCB1 and only H460 cells 
express ABCG2.  
Dox accumulation assays were performed on all three cancer cell lines, 
A549, H460, and HeLa.  Cells were pretreated with vehicle alone, MK571 (MRP1 
inhibitor), TBBz (CK2 inhibitor), FTC (ABCG2 inhibitor) and PSC883 (ABCB1 
inhibitor) (Figure 3.2B). Using MK571 to inhibit the function of MRP1we found a 
significant increase in Dox accumulation in all cell lines. TBBz-pretreatments 
resulted in Dox accumulation that was significantly higher than in untreated cells 
and lower than in MK571 treated cells. Co-administration of TBBz and MK571 
resulted in Dox accumulation that was similar to what was achieved by treatment 
of the cells with MK571 alone, suggesting a MRP1-dependent mechanism of 
action for TBBz. Pretreatment of cells with the ABCB1 inhibitor, PSC833, and the 
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ABCG2 inhibitor, FTC, did not increase Dox accumulation.  This result confirms 
that ABCB1 and ABCG2 do not play a role in Dox efflux in these cells (Figure 
3.2B). This is expected due to the fact that no cell lines used expressed ABCB1 
or ABCG2, except H460, which expressed ABCG2 in low levels (Figure 3.2A). It 
has been found that only a mutated form of ABCG2 (R482T/G) can transport 
doxorubicin. Since ABCG2 is expressed in H460’s but no change in Dox was 
found, it is reasonable to conclude that the ABCG2 expressed isn’t the mutant 
form that has been found to be able to transport Dox.  
Based on increased accumulation of Dox in the cells when inhibited by 
TBBz, it would be expected there would be an increase in cellular cytotoxicity. 
Using 3-[4,5-dimethylthiazol-2-y]-2,5 diphenyl tetrazolium bromide (MTT) assays 
to measure cytotoxicity, we found that the sensitivity/cytotoxicity to Dox was 
increased when HeLa, H460, and A549 cells were pretreated with MK571 or 
TBBz (Figure 3.2C and Table 3.1).  Pretreatment of cells with both MK571 and 
TBBz showed no additional cytotoxicity compared to MK571 treatment alone. If 
Dox accumulation is dependent on MRP1, then co-treatment of cells with TBBz 
and MK571 would not increase cytotoxicity of Dox beyond what is achieved by 
using MK571 alone. 
The data from this study compliments additional studies from our lab that 
utilized a knockdown of CK2α in MCF7-derived cells expressing MRP1, where 
doxorubicin sensitivity was increased (115). In these studies other substrates for 
MRP1, such as leukotriene C4 and estradiol-17β-D-glucuronide , were found to 
have decreased transport during CK2α knockdown (115). Additionally, in MRP1 
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where Thr249 was mutated to an alanine decreased MRP1-mediated transport 
was found(115). Another mutation Thr249E was found to increase the MRP1-
mediated transport, where Thr249E is a phosphomimicking mutation (115). From 
these studies using mutations in MRP1, combined with the additional data to 
support CK2α regulation of MRP1 transport, it was concluded that CK2α 
regulates MRP1 by phosphorylation at Thr249 (115).  
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Discussion: 
In this study we present data that strongly suggest that CK2α regulates 
MRP1 function in humans. This finding is clinically important because MRP1 and 
CK2 have been found to be upregulated in a variety of cancer types, such as, 
leukemia, prostate, breast and lung (1, 58). The key finding of this study is that 
MRP1 function can be downregulated by inhibitors of CK2α. Inhibition of CK2α 
by TBBz resulted in decreased MRP1 function and increased cytotoxicity when 
cells were exposed to Dox. Additionally, inhibiting CK2α in combination with 
MRP1 inhibition did not result in an additive decrease in MRP1 function or 
cytotoxicity compared to utilizing an inhibitor for MRP1 alone. This is most likely 
due to the fact that the inhibitor for CK2α, TBBz, is only impacting MRP1 function 
and not other ABC transporters in relation to increased Dox accumulation and 
increased Dox cytotoxicity in these cell lines.  
To our knowledge, this is the first study to show that CK2α regulates 
MRP1 function.  A number of studies have shown that upregulation of CK2α in 
cancer correlates very strongly with multidrug resistance and cancer relapse. 
Our studies suggest that upregulation of MRP1 function is one mechanism by 
which overexpression of CK2α results in increased cancer multidrug resistance 
and a higher risk of relapse. Additional work from our lab has shown that CK2α 
regulates MRP1 function via phosphorylation at Thr249 (115). This work used 
two cell lines: a knockdown of CK2α in MRP1 expressing MCF7 cells, as well as, 
a mutation of Thr249 to alanine in MRP1 expressing MCF7 cells. Both the 
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knockdown and mutated cell lines showed increased sensitivity to Dox. In 
Chapter 3, using human cancer cell lines that natively express MRP1 and CK2, 
we found that inhibitors for CK2α could decrease MRP1 function. This finding 
supported the finding found in the mutant cell lines, and therefore together 
strongly suggest a role for CK2α regulation of MRP1 in cancer. 
 Overall the study presented in Chapter 3 has revealed that inhibition of 
CK2α can downregulate the function of MRP1 in several cancer cell lines leading 
to increased sensitivity to MRP1-mediated transport of chemotherapeutics. In the 
future we hope to further explore the therapeutic benefits of regulating MRP1 
function through the use of CK2α inhibitors. Furthermore, we hope to conduct 
additional experiments in other cancer cell types, such as leukemia, to see if 
MRP1 function can be regulated by CK2α inhibitors. It would also be interesting 
to see if CK2α inhibitors could produce the same phenotype as our MRP1-/- mice 
with increased numbers and self-renewal capacity of HSCs. 
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Figure 3.1A Ycf1p is regulated by Cka1p-mediated phosphorylation of 
Ser251. Ycf1p consists of 3 MSDs and 2 NBDs. Ycf1p is phosphorylated at 
Ser251 by Cka1p (66).  
Figure 3.1BSequence homology in the L0 region between Ycf1p and MRP1. 
Close analysis of the sequences of Ycf1p and MRP1 L0 regions by sequence 
alignment (using ClustalW2) show that a homologous putative phosphorylation 
site to Ycf1p Ser 251 can be found at MRP1 Thr249 
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Figure 3.2(115) 
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Figure 3.2 CK2α can decrease MRP1 function in cancer cell lines resulting 
in increased sensitivity to chemotherapeutics. A) Western Blot analysis of 
MRP1, ABCB1, ABCG2, and CK2 in HeLa, H460 and A549 cell lines. An 
ABCB1-expressing cell line was loaded as a positive control for immunoblotting 
of ABCB-1B) Doxorubicin accumulation assay using the inhibitors MK571 
(MRP1) TBBz (CK2), PSC833 (ABCB1) and FTC (ABCG2) as described in the 
Materials and Methods section. Statistical analysis for this assay was done using 
an ANOVA followed by Bonferroni. C). MTT assays measuring the cytotoxicity of 
Dox using the inhibitors MK571, TBBz, and MK571+TBBz as described in the 
Materials and Methods section. Logistic nonlinear regression curves were 
generated with Graphpad Prism5.  
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Table 3.1 Comparison of AUC, IC50 and IC90 of cell lines in Figure 3.2(115) 
Treatment AUC IC50 95% CI IC90 95% CI 
H
eL
a 
Control 2,083 ~ 1925 (Very wide) ~ 1664 (Very wide) 
C
el
l l
in
e 
+MK571 896 697 637.2 to 762.4 384.2 327.7 to 450.5 
+TBBz 1,255 1057 903.6 to 1236 797.6 441.8 to 1440 
+MK571+TBBz 699 613 521.1 to 721.1 281.4 203.2 to 389.7 
H
46
0 
Control 1,038 390.5 303.5 to 502.6 48.52 27.94 to 84.25 
+MK571 575 116 105.1 to 127.9 53.38 43.35 to 65.72 
+TBBz 929 243.4 186.9 to 317.0 13.93 6.882 to 28.18 
+MK571+TBBz 660 125.3 101.3 to 154.9 28.05 17.38 to 45.28 
A
54
9 
Control 2,117 1.634e+006 (Very wide) ~ 271.4 (Very wide) 
+MK571 1,557 280.8 112.4 to 701.6 4.36 0.2873 to 66.11 
+TBBz 1,632 ~ 13412 (Very wide) 0.87 0.0024 to 317.2 
+MK571+TBBz 1,466 98.81 42.72 to 228.5 1.59 0.0793 to 31.99 
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Chapter 4 
Discussion 
Hematopoiesis: The Role of MRP1 
The most characterized ABC transporter in HSCs is ABCG2.  ABCG2 is 
expressed at relatively high levels in LT-HSCs and decreases throughout the 
early stages of HSCs differentiation (83, 88, 116, 117). Deletion of ABCG2 in 
mice results in decreased HSCs self-renewal and differentiation (83, 116).  
MRP1 is also expressed in HSCs, however the expression pattern of MRP1 is 
opposite that of ABCG2 with lower levels in LT-HSCS and increasing throughout 
the early stages of differentiation, at both the protein and mRNA level (84, 117) 
(Figure 2.5A).  This finding implies that, similar to ABCG2, MRP1 plays a role in 
regulating HSC self-renewal and differentiation.  A number of studies have 
shown that MRP1 plays a role in regulating differentiation and self-renewal in a 
variety of early stem cell types, including dendritic and endothelial progenitor 
cells (118, 119). For example, in the endothelial progenitor cells (EPCs) it was 
found that changes in the redox homeostasis caused by MRP1 expression would 
lead to decreased function and survival of the EPCs (120).  Based on these 
findings, we hypothesized that MRP1 regulates HSC self-renewal and 
differentiation.  To determine if MRP1 does regulate HSC self-renewal and 
differentiation, we utilized C57BL6 MRP1-/- and MRP1+/+ mice. C57BL6 mice 
have served as the research model of choice for HSC studies in hematopoiesis 
for over 40 years, largely due to a limiting ability for HSCs to self-renew in culture 
86 
(121, 122). C57BL/6 mice (CD45.2) and B6.SJL-Ptprca Pepcb/BoyJ mice 
(CD45.1) are used in HSC transplants. The B6.SJL-Ptprca Pepcb/BoyJ mice were 
derived from C57BL/6 mice to express CD45 variant (also known as Ly5 and 
Ptprc) to make them easily distinguishable by flow-cytometry (121, 122).  
The most exciting finding presented in Chapter 2 is that MRP1 regulates 
HSC self-renewal and differentiation. Using serial dilution competitive 
repopulation assays, we found that deletion of MRP1 increases the ability of 
HSCs to repopulate BM of lethally irradiated mice. Our studies strongly support 
that the mechanism by which MRP1 regulates HSC self-renewal is via regulation 
of cellular GSH levels.  Here in our work, deletion of MRP1 results in increased 
GSH levels, decreased cellular ROS, decreased p38 signaling, and altered redox 
response protein expression.  Using a GSH mimetic NAC, we were able to 
recapitulate the MRP1-/- phenotype of increased LT-HSCs and ST-HSCs, and 
decreased ROS. Importantly, we determined that upregulation of MRP4 
expression is not a mechanism by which the HSCs compensate for the loss of 
MRP1 expression. Overall the data presented in Chapter 2 strongly support a 
role for MRP1 in regulating HSC self-renewal via efflux of GSH and subsequent 
reduction of ROS. 
 
Post-translational regulation of MRP1 
Our laboratory has previously established that Cka1p can phosphorylate 
Ycf1p at Ser251(66).  Ycf1p and MRP1 are highly homologous within the L0 
region.  MRP1 contains a putative phosphorylation site at Thr249 that aligns with 
Ser251 in Ycf1p.  Based on these findings in yeast and the high degree of 
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homology within the L0 of Ycf1p and MRP1, we hypothesized that CK2 regulates 
MRP1 function in humans via phosphorylation at Thr249 (Figure 3.1). 
The most exciting finding, presented in Chapter 3, is that treatment of 
cancer cell lines with an inhibitor of CK2α decreases MRP1 function in three 
different cancer cell lines.  Further, decreased function correlates with a loss of 
MRP1-mediated protection from Dox cytotoxicity. Using inhibitors to both ABCG2 
and ABCB1 we have ruled out the possibility that ABCB1 and ABCG2 transport 
of Dox, respectively, plays a role in our study outcomes and that our results are 
indeed dependent on MRP1. The worked described in chapter 3 together with 
additional analyses provided by Dr. Ela Stolarczyk (a postdoctoral fellow in the 
Paumi lab) shows that MRP1 function is regulated by CK2α via phosphorylation 
of Thr249 (115).  
  
Future Directions: Targeting MRP1 to Enhance Therapeutic Outcomes 
A number of studies suggest that if ROS production is limited, then self-
renewal is increased in the HSCs.  These HSCs low in ROS should transplant 
more efficiently and better repopulate the BM niche. Drugs that alter ROS, such 
as Niclosamide, are currently being developed for leukemia treatment based on 
their abilities to target leukemic stem cells (LSCs) (49). Niclosamide is a 
chemotherapeutic that increases ROS levels, and has been shown to selectively 
kill CD34+/CD38− AML stem cells, while having minimal cytotoxicity against 
normal HSCs (49) .  
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  It is hypothesized that if MRP1-/- HSCs were used for bone marrow 
transplants that chemotherapeutics that normally spare healthy HSCs would 
starttargeting them, as well as LSCs, due to altered levels of ROS.  If this 
hypothesis is true, any benefit from using MRP1-/- HSCs for bone marrow 
transplants would be negated if transplant patients were also on 
chemotherapeutics, such as Niclosamide that alter ROS.  Alternatively, it has 
been shown that high levels of cellular GSH decrease chemotherapy 
effectiveness (49). Since MRP1-/- HSCs have more GSH it is just as likely that 
those HSCs may be to a greater extent spared from chemotherapeutics.  
Interestingly, GSH is elevated in a variety of cancer types, including 
leukemia, breast, colon, larynx, and lungs (123). This increase in GSH is thought 
to allow cancer cells to withstand ionizing radiation treatments and afford 
resistance to a variety of chemotherapeutic drugs (123). We have hypothesized 
that deletion or downregulation of MRP1 in leukemic stem cells (LSCs), where 
MRP1 downregulation is found in some subtypes of AML (that have an inversion 
of chromosome 16), will result in increased resistance to drug treatments due an 
increased cellular GSH content that would prevent redox cycling, and therefore 
toxicity, of many of the standard chemotherapeutics used in the clinic today that 
work based on increasing ROS levels.  
 Our lab has carried-out pilot studies using short-term 24-hour exposure of 
mice to Dox and found no significant differences between MRP1-/- and MRP1+/+ 
HSC numbers. In the clinic most patients are exposed for a longer time to 
chemotherapeutics and this long-term exposure might be selective for 
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enrichment of MRP1-/- LSCs. Longer exposure to chemotherapeutics in mice will 
allow us to elucidate whether there is enhanced selectivity to MRP1-/- LSCs.  
Bone marrow transplants are not limited to cancer patients and are an 
important part of the treatments for bone marrow failure and a number of other 
hematological diseases, such as sickle cell anemia and autoimmune disorders. 
Therefore, it would be interesting to evaluate other types of drugs that are used 
concurrently with bone marrow transplants. This evaluation would ensure drug 
combinations used with transplants would not lead to increased cellular stress, 
which is known to lead to diseases such as cancer, cardiovascular disease, and 
aging. 
 Currently our lab is in the process of developing a leukemic mouse model 
to study the role of MRP1 in regulating LSC self-renewal and differentiation in 
acute myeloid leukemias (AMLs), due to MRP1 being downregulated inAML 
patients with an inversion of chromosome 16 (124). Based on the findings 
described in Chapter 2 that MRP1-/- mice HSCs have increased self-renewal and 
an increased ability to repopulate the bone marrow niche, it is anticipated that 
MRP1-/- LSCs would also have these characteristics. This would make MRP1-/- 
LSCs much more aggressive than MRP1+/+ LSCs. It is also anticipated that 
MRP1-/- LSCs will have lower ROS levels due to the increase in GSH levels that 
results from deletion of MRP1. If this is true it would be important to evaluate how 
MRP1-/- LSCs respond to chemotherapeutics that target and/or alter ROS. Since 
LSCs already have low levels of ROS it may appear that MRP1-/- LSCs, with even 
lower levels of ROS, could be better targeted by chemotherapeutics, such as 
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niclosamide, that target and/or alter ROS by increasing it; however, if the 
decrease in ROS is due tohigher GSH levels, which are anticipated in MRP1-/- 
LSCs, chemotherapeutics that target ROS would become less effective(49). 
 Previous studies have found that leukemia cell lines differentiate towards 
megakaryocytes (107). This preferred differentiation towards megakaryocytes 
was also observed in MRP1-/- mice.  It should be investigated if the lack of MRP1 
is causing the shift to megakaryocyes, or if there is another cause for this shift. 
Alternatively, a very recent study has proposed that most HSCs will preferentially 
differentiate towards megakaryocytes, without the loss of self-renewal capacity in 
HSCs (106). If this is true it would be plausible that simply increasing the amount 
of self-renewal in HSCs will increase megakaryocytes.   
 The increase in megakaryocyte progenitors in MRP1-/- mice was 
accompanied by a doubling of the platelets compared to MRP1+/+ mice. It would 
be interesting to investigate if the MRP1-/- platelets demonstrate any alteration in 
their normal function, such as clotting ability.  Phosphatidylserine (PS), which 
plays a role in clotting by enhancing the activation of prothrombin to thrombin, 
has been shown to increase with increased ROS exposure (125). Since MRP1-/- 
mice have lower levels of ROS it would be anticipated that they have lower levels 
of PS as compared to MRP1+/+ mice. A decrease in clotting ability due to lower 
PS levels is a possible explanation for increased platelets to maintain normal 
platelet function in the MRP1-/- mice.   
 In the future, the Paumi lab would like to determine if CK2α regulates 
MRP1 function in HSCs.  These future studies will have an immediate impact on 
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the treatment of multiple cancers.  Currently, inhibitors of CK2 are under 
development for treatment of leukemia due to their ability to target leukemic 
cancer cells and potentially LSCs, while sparing healthy cells. HSCs and LSCs 
reside in a highly protective BM microenvironment and care should be taken to 
ensure the inhibitors can successfully penetrate the niche. 
 In conclusion, MRP1 plays a role in the regulation of HSC differentiation 
and self-renewal. Further studies are warranted to elucidate whether or not 
MRP1 can be targeted to enhance the therapeutic treatment of those with bone 
marrow disease.  
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Appendix A: Solutions 
1 L Red Cell Lysis Buffer: 
8.02 g NH4Cl 
0.84 g NaHCO3 
2 mL 0.5M EDTA 
Directions: Combine the above ingredients and dilute to 1 L. Filter sterile 
before use and store at 4 degrees. 
Facs Buffer: 
PBS+2%FBS 
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Appendix B: FACS Bone Marrow Staining 
 
1. Extract Bone Marrow from Femur and Tibias of mice  
a. To do this simply fill a syringe with FACs buffer and flush the 
contents of the bone from one end out the other into a tube.           
2. Lyse Bone Marrow cells in RBC lysis buffer. 
3. Spin down lysed cells at 1600 rpms for 3 minutes. 
4. Wash cell pellet 2x with FACS buffer (PBS +2%FBS) 
5. Resuspend pellet in 500 μL of FACS buffer and filter in blue cap Falcon 
FACS tube. 
6. Spin cells down again at 1600 rpm for 3 min. 
7. Resuspend cells in 100 μL of FACS buffer with appropriate Ab added 
except Dapi.  See Tables below. (all antibodies are used at 1:50 dilutions 
except Flt-3 which is at 1:25 dilution) 
 
 
 
 
 
 
 
 
 
 
*Here Lin- represents B220, CD3, Ter199, and Gr1 
 
8. Incubate on ice covered in aluminum foil for 60 minutes. 
9. Spin cells down at 1600 rpm for 3 minutes 
10. Wash cells 1x in 500 μL of FACS buffer 
11. Resuspend cells in 100uL FACs buffer and add 5 μg/mL of Dapi 
12. Flow analysis in one hour 
 
 
*Please Note: When staining bone marrow used during transplantion 
studies the antibody for CD45.2 must be used in the panel. For APC CD45.2 
simply omit CD150.  
 
Dye  
PE CD135 
FITC CD34 
PerCP-Cy5.5 c-Kit 
PE-Cy7 Sca-1 
APC/Alexa647 CD150 
APC-Cy7 Lineage 
DAPI + 
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Appendix C:FACS Peripheral Blood Staining 
 
1. Collect blood in EDTA lined collection tube 
1. Typically by submandibular cheek bleed but eye bleeds can also be 
used.           
2. Add FACs buffer to collection tube to help avoid clotting 
3. Spin down cells 1600 rpms for 3 minutes. 
4. Remove the top layer from the tubes (the FACS buffer) 
5. Lyse with red cell lysis buffer 
6. Centrifuge 1600 rpm for 3 min 
7. Wash with 500 μL of FACS buffer 
8. Centrifuge at 1600 rpm for 3 min  
9. Resuspend cells in 100 μL of FACS buffer with appropriate Ab.  See 
Tables below. (all antibodies are used at 1:50 dilutions) 
 
 
 
 
 
 
 
 
 
 
 
 
10. Incubate on ice covered in aluminum foil for 60 minutes. 
11. Spin cells down at 1600 rpm for 3 minutes 
12. Wash cells 1x in 500 μL of FACS buffer 
13. Resuspend in 500 μL of FACS buffer 
14. Flow analysis in one hour 
 
 
*Please Note: CD45.1 and CD45.2 only used in peripheral blood staining 
from transplantation studies.  
 
 
 
 
 
 
 
 
Dye  
PE CD45.1 
PerCP-Cy5.5 CD19 
PE-Cy7 CD3e 
APC/Alexa647 CD 45.2 
APC-Cy7 CD11b 
DAPI V450 
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Appendix D: FACS MCB Staining (Glutathione) 
 
1. Extract Bone Marrow from Femur and Tibias of mice. 
2. Lyse Bone Marrow cells in RBC lysis buffer. 
3. Spin down lysed cells at 1600 rpms for 3 minutes. 
4. Wash cell pellet 2x with FACS buffer (PBS +2%FBS) 
5. Resuspend pellet in 500 μL of FACS buffer and filter in blue cap Falcon 
FACS tube. 
6. Spin cells down again at 1600 rpm for 3 min. 
7. Resuspend cells in 100 μL of FACS buffer with appropriate Ab added 
except MCB.  See Tables below. (all antibodies are used at 1:50 dilutions 
except Flt-3 which is at 1:25 dilution) 
 
 
 
 
 
 
 
 
 
 
*Here Lin- represents B220, CD3, Ter199, and Gr1 
 
8. Incubate on ice covered in aluminum foil for 60 minutes. 
9. Spin cells down at 1600 rpm for 3 minutes 
10. Wash cells 1x in 500 μL of FACS buffer 
11. Resuspend cells in 100uL RPMI1640/10%FBS with 50uM MK571 for 60 
min 
12.  Resuspend cells in 100uL RPMI1640/10%FBS with 50uM  MK571 + MCB 
(1:5000 dilution using 25mM stock) 20 min 37 degrees C 
13. Wash with 3 mL ice cold FACS buffer 1600 RPMI’s for 3 min 
14. Resuspend in 500 μL of FACS buffer containing 50uM MK571 and  5 
μg/mL of DAPI 
15. Flow analysis in one hour 
 
 
 
 
 
 
Dye  
PE CD135 
FITC CD34 
PerCP-Cy5.5 c-Kit 
PE-Cy7 Sca-1 
APC/Alexa647 CD150 
APC-Cy7 Lineage 
DAPI MCB 
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Appendix E: FACS DCF-DA Staining (Intracellular ROS) 
 
1. Extract Bone Marrow from Femur and Tibias of mice. 
2. Lyse Bone Marrow cells in RBC lysis buffer. 
3. Spin down lysed cells at 1600 rpms for 3 minutes. 
4. Wash cell pellet 2x with FACS buffer (PBS +2%FBS) 
5. Resuspend pellet in 500 μL of FACS buffer and filter in blue cap Falcon 
FACS tube. 
6. Spin cells down again at 1600 rpm for 3 min. 
7. Resuspend cells in 100 μL of FACS buffer with appropriate Ab added 
except DCF-DA.  See Tables below. (all antibodies are used at 1:50 
dilutions except Flt-3 which is at 1:25 dilution) 
 
 
 
 
 
 
 
 
 
 
*Here Lin- represents B220, CD3, Ter199, and Gr1 
 
8. Incubate on ice covered in aluminum foil for 60 minutes. 
9. Spin cells down at 1600 rpm for 3 minutes 
10. Wash cells 1x in 500 μL of FACS buffer 
11. Resuspend cells in 100uL RPMI1640/10%FBS with 50uM MK571 for 60 
min 
12. Resuspend cells in 100uL RPMI1640/10%FBS with 50uM  MK571 + DCF-
DA (1:5000 dilution using 25mM stock) 10-15 min 37 degrees C 
13. Wash with 3 mL ice cold FACS buffer 1600 RPMI’s for 3 min 
14. Resuspend in 500 μL of FACS buffer containing 50uM MK571 and  5 
μg/mL of DAPI 
15. Flow analysis in one hour 
 
 
 
 
 
 
 
 
 
 
 
Dye  
PE CD135 
FITC DCF-DA 
PerCP-Cy5.5 c-Kit 
PE-Cy7 Sca-1 
APC/Alexa647 CD34 
APC-Cy7 Lineage 
DAPI + 
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Appendix F: Intracellular Protein expression via FACS 
 
a. Follow Bone Marrow staining as normal making sure panel doesn’t 
contain color that intracellular protein of interest uses. 
b. After incubating with extracellular antibodies wash with 1 mL FACs 
buffer and centrifuge at 1600 rpm for 3 min 
c. Resuspend pellet in 1mL fixation and permeabilization solution 
d. Incubate for 60 min in foil covered ice 
e. Rinse twice with 1 mL permeabilization buffer 
f. Block with 2 uL of FBS in 100 uL permeabilization buffer on foil 
covered ice for 15 minutes 
g. Add antibody of interest-2 uL in 100 uL permeabilization buffer and 
incubate on foil covered ice 
i. 4 hours for transporter proteins 
ii. 0vernight for ROS proteins 
h. Wash with permeabilization buffer and centrifuge at 1600 rpm for 3 
min 
i. Add secondary antibody for 15 minues 
j.  Resuspend in 500 uL FACS buffer-analyze via facs 
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Appendix G: List of Abbreviations. 
ABC         ATP-binding cassette 
ATF2         Activating Transcription Factor 2 
ATP        Adenosine triphosphate 
BA         Basophil 
BFU         Blast Forming Unit 
BM          Bone Marrow 
BMMC        Bone Marrow Mononuclear Cells 
BSO          Buthionine sulphoximine 
CAT        Catalase 
CFC         Colony Forming Cell Assay 
CFTR          Cystic Fibrosis Transductance Regulator 
CFU         Colony Forming Units 
CFU-GEMM   Colony Forming Unites granulocyte, 
  Erythrocyte, Monocyte, megakaryocyte   
CFU-GM    Colony Forming Units –Granulocyte 
       Macrophage 
CLP       Common Lymphoid Progenitor 
CMP      Common Myeloid Progenitor 
CRU        Competitive Repopulating Unit 
DCF-DA        Dichloro-fluorescein diacetate 
DOX       Doxorubicin 
EDTA         Ethylene diamine tetraacetic acid 
EO     Eosinophil 
EPC        Endothelial Progenitor Cells 
ESC        Embryonic Stem Cells 
FACS       Fluorescence-activated cell sorting 
FBS      Fetal Bovine Serum 
FITC      Fluorescein isothiocyanate 
FTC       Fumitremorgin C 
GCLC     Glutamyl Cysteine Ligase Catalytic 
GCLM       Glutamyl Cysteine Ligase Modulary 
GPx      Glutathione Peroxidase 
GR/GSR       Glutathione Reductase 
GSH     Glutathione (reduced form) 
GSS      Glutathione Synthetase 
GSSG    Glutathione disulfide (Oxidized form) 
GS-X     Glutathione Conjugated 
Gy    Gray 
HB       Hemoglobin 
HCT       Hematocrit 
H2O2      Hydrogen Peroxide 
HSC       Hematopoietic Stem Cells 
IP     Intraperitoneal 
IMDM 
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kDA                                                          Kilodalton 
KO                                                            Knockout 
O3                                                             Ozone 
OH                                                            Hydroxide 
LSC                                                          Leukemic Stem Cell 
LSK                                                          Lin-, C-kit+, Sca-1+ (HSCs) 
LT-HSC                                                    Long-term HSC 
LTC4                                                        Leukotriene C4 
LY                                                            Lymphocyte 
M                                                             Molar 
MAPK                                                      Mitogen-activated Protein Kinase 
MAPkKAP                                                Mitogen-activated Protein Kinase         
                                                                          Activated Protein Kinase 
MCB                                                         Monochlorbimane 
MCH                                                         Mean corpuscular hemoglogin 
MCHC                                                      Mean corpuscular hemoglobin 
                                                                            concentration 
MCV                                                         Mean corpuscular volume 
MDR                                                         Multi drug resistance 
MEF2                                                      Myocyte Enhancer Factor 2 
MEP                                                        Megakaryocyte Erythroid Progenitor 
Mg                                                           Milligram 
MKK                                                        Mitogen activated protein kinase kinase 
mLMilliliter 
mMMillimolar 
μM                                                          Micromolar 
MO                                                          Monocyte 
MNBC                                                     Mononuclear Blood Cells 
MPP                                                        Multipotent Progenitor 
MPV                                                        Mean platelet volume 
MRP1                                                      Multidrug resistance associated protein 1 
Mrp1-/-                                                     Mrp1 knock out 
MRP4                                                      Multidrug resistance associated protein 4 
MSD                                                        Membrane spanning domain 
MSK1/2                                                   Mitogen and stress activated protein  
                                                                             Kinase 1 and 2 
MTT                                                         3-(4,5-dimethylthiazol-2-yl)-2,5 
NAC                                                         N-acetyl cysteine 
NBD                                                         Nucleotide binding domain 
NE                                                            Neutrophil 
Nrf2                                                         Nuclear factor-like 2 
NK                                                           Natural Killer 
NOX                                                        NADPH Oxidase 
PB                                                           Peripheral Blood 
PBS                                                        Phosphate Buffer Saline 
PGP                                                        P-glycoprotein 
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PI     Propidium Iodide 
PLT       Platelet 
PMSF     Phenylmethylsulfonyl fluoride 
PS      Phosphatidylserine 
RBC        Red Blood Cell 
RDW      Red cell distribution width 
ROS      Reactive oxygen species 
SDS        Sodium dodecyl sulfate 
SOD1     Copper-Zinc superoxide dismutase 
SOD2     Manganese superoxide dismutase 
SUR1        ABBC8 
TBBz   tetrabomobenzimidazole 
TBST      Tris-Buffered Saline + Tween 
TM    Transmembrane 
TMD      Transmembrane domain 
TNFα     Tumor Necrosis Factor Alpha 
WBC     White Blood Cell 
WT     Wild-type 
YCF1        Yeast Cadmium Factor Protein 1 
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